Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.
A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.
An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.
Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the transmitter. Blocking uptake may also deplete available transmitter stores. Many clinically important drugs are uptake inhibitors although the indirect reactions of the brain rather than the acute block of uptake itself is often responsible for the therapeutic effects.
Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of dopaminergic neurons. They remove DOPAMINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS and are the target of DOPAMINE UPTAKE INHIBITORS.
Piperazines are a class of heterocyclic organic compounds containing a seven-membered ring with two nitrogen atoms at positions 1 and 4, often used in pharmaceuticals as smooth muscle relaxants, antipsychotics, antidepressants, and antihistamines, but can also be found as recreational drugs with stimulant and entactogen properties.
A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES.
Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells.
A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D1-class receptor genes lack INTRONS, and the receptors stimulate ADENYLYL CYCLASES.
Drugs that bind to and activate dopamine receptors.
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
Pinched-off nerve endings and their contents of vesicles and cytoplasm together with the attached subsynaptic area of the membrane of the post-synaptic cell. They are largely artificial structures produced by fractionation after selective centrifugation of nervous tissue homogenates.
A subtype of dopamine D2 receptors that are highly expressed in the LIMBIC SYSTEM of the brain.
Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE.
Compounds that suppress or block the plasma membrane transport of GAMMA-AMINOBUTYRIC ACID by GABA PLASMA MEMBRANE TRANSPORT PROTEINS.
N-methyl-8-azabicyclo[3.2.1]octanes best known for the ones found in PLANTS.
Membrane proteins whose primary function is to facilitate the transport of molecules across a biological membrane. Included in this broad category are proteins involved in active transport (BIOLOGICAL TRANSPORT, ACTIVE), facilitated transport and ION CHANNELS.
Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of noradrenergic neurons. They remove NOREPINEPHRINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. It regulates signal amplitude and duration at noradrenergic synapses and is the target of ADRENERGIC UPTAKE INHIBITORS.
Collection of pleomorphic cells in the caudal part of the anterior horn of the LATERAL VENTRICLE, in the region of the OLFACTORY TUBERCLE, lying between the head of the CAUDATE NUCLEUS and the ANTERIOR PERFORATED SUBSTANCE. It is part of the so-called VENTRAL STRIATUM, a composite structure considered part of the BASAL GANGLIA.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)
Nipecotic acids are a class of compounds, specifically GABAergic drugs, that act as reversible inhibitors of the presynaptic GABA transporter (GAT), increasing the concentration of GABA in the synaptic cleft and enhancing its inhibitory effects on neurotransmission.
A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.
A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Compounds that specifically inhibit the reuptake of serotonin in the brain.
The phylogenetically newer part of the CORPUS STRIATUM consisting of the CAUDATE NUCLEUS and PUTAMEN. It is often called simply the striatum.
A technique for measuring extracellular concentrations of substances in tissues, usually in vivo, by means of a small probe equipped with a semipermeable membrane. Substances may also be introduced into the extracellular space through the membrane.
'Nerve tissue proteins' are specialized proteins found within the nervous system's biological tissue, including neurofilaments, neuronal cytoskeletal proteins, and neural cell adhesion molecules, which facilitate structural support, intracellular communication, and synaptic connectivity essential for proper neurological function.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
A subtype of dopamine D1 receptors that has higher affinity for DOPAMINE and differentially couples to GTP-BINDING PROTEINS.
Glycoproteins found on the membrane or surface of cells.
The physical activity of a human or an animal as a behavioral phenomenon.
A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
An alkaloid that has actions similar to NICOTINE on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation.
The observable response an animal makes to any situation.
A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
Elongated gray mass of the neostriatum located adjacent to the lateral ventricle of the brain.
The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments.
Dopamine beta-Hydroxylase is an enzyme that catalyzes the conversion of dopamine to norepinephrine, a crucial step in the synthesis of catecholamines within the adrenal glands and central nervous system.
A family of vesicular amine transporter proteins that catalyze the transport and storage of CATECHOLAMINES and indolamines into SECRETORY VESICLES.
Agents that affect ION PUMPS; ION CHANNELS; ABC TRANSPORTERS; and other MEMBRANE TRANSPORT PROTEINS.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Biogenic amines having only one amine moiety. Included in this group are all natural monoamines formed by the enzymatic decarboxylation of natural amino acids.
A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
A drug formerly used as an antipsychotic and treatment of various movement disorders. Tetrabenazine blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system.
The middle of the three primitive cerebral vesicles of the embryonic brain. Without further subdivision, midbrain develops into a short, constricted portion connecting the PONS and the DIENCEPHALON. Midbrain contains two major parts, the dorsal TECTUM MESENCEPHALI and the ventral TEGMENTUM MESENCEPHALI, housing components of auditory, visual, and other sensorimoter systems.
A monoamine oxidase inhibitor with antihypertensive properties.
Relatively invariant mode of behavior elicited or determined by a particular situation; may be verbal, postural, or expressive.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis.
Disorders related or resulting from use of cocaine.
Transport proteins that carry specific substances in the blood or across cell membranes.
The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM.
A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy.
A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.
An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
A pharmacologic congener of serotonin that contracts smooth muscle and has actions similar to those of tricyclic antidepressants. It has been proposed as an oxytocic.
An active neurotoxic metabolite of 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE. The compound reduces dopamine levels, inhibits the biosynthesis of catecholamines, depletes cardiac norepinephrine and inactivates tyrosine hydroxylase. These and other toxic effects lead to cessation of oxidative phosphorylation, ATP depletion, and cell death. The compound, which is related to PARAQUAT, has also been used as an herbicide.
Analogs or derivatives of AMPHETAMINE. Many are sympathomimetics and central nervous system stimulators causing excitation, vasopressin, bronchodilation, and to varying degrees, anorexia, analepsis, nasal decongestion, and some smooth muscle relaxation.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
A dopamine D2/D3 receptor agonist.
Administration of a drug or chemical by the individual under the direction of a physician. It includes administration clinically or experimentally, by human or animal.
A serotonin uptake inhibitor that is effective in the treatment of depression.
Tritium is an isotope of hydrogen (specifically, hydrogen-3) that contains one proton and two neutrons in its nucleus, making it radioactive with a half-life of about 12.3 years, and is used in various applications including nuclear research, illumination, and dating techniques due to its low energy beta decay.
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.
Compounds with BENZENE fused to AZEPINES.
Dicarboxylic acids are organic compounds containing two carboxyl (-COOH) groups in their structure, making them capable of forming salts and esters by losing two hydrogen ions.
A deaminated metabolite of LEVODOPA.
Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states.
The rate dynamics in chemical or physical systems.
The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.
An indirect sympathomimetic. Tyramine does not directly activate adrenergic receptors, but it can serve as a substrate for adrenergic uptake systems and monoamine oxidase so it prolongs the actions of adrenergic transmitters. It also provokes transmitter release from adrenergic terminals. Tyramine may be a neurotransmitter in some invertebrate nervous systems.
A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.
Elements of limited time intervals, contributing to particular results or situations.
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)
Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of serotonergic neurons. They are different than SEROTONIN RECEPTORS, which signal cellular responses to SEROTONIN. They remove SEROTONIN from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. Regulates signal amplitude and duration at serotonergic synapses and is the site of action of the SEROTONIN UPTAKE INHIBITORS.
A furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action.
The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
Pyrrolidines are saturated, heterocyclic organic compounds containing a five-membered ring with four carbon atoms and one nitrogen atom (NRCH2CH2), commonly found as structural components in various alkaloids and used in the synthesis of pharmaceuticals and other organic materials.
A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.
Amides of salicylic acid.
A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
The most common inhibitory neurotransmitter in the central nervous system.
A general class of ortho-dihydroxyphenylalkylamines derived from tyrosine.
Membrane-bound compartments which contain transmitter molecules. Synaptic vesicles are concentrated at presynaptic terminals. They actively sequester transmitter molecules from the cytoplasm. In at least some synapses, transmitter release occurs by fusion of these vesicles with the presynaptic membrane, followed by exocytosis of their contents.
A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
Fatty acid derivatives that have specificity for CANNABINOID RECEPTORS. They are structurally distinct from CANNABINOIDS and were originally discovered as a group of endogenous CANNABINOID RECEPTOR AGONISTS.

Solid-phase microextraction for cannabinoids analysis in hair and its possible application to other drugs. (1/1361)

This paper describes the application of solid-phase microextraction (SPME) to cannabis testing in hair. Fifty milligrams of hair was washed with petroleum ether, hydrolyzed with NaOH, neutralized, deuterated internal standard was added and directly submitted to SPME. The SPME was analyzed by GC-MS. The limit of detection was 0.1 ng/mg for cannabinol (CBN) and delta9-tetrahydrocannabinol (THC) and 0.2 ng/mg for cannabidiol (CBD). THC was detected in a range spanning from 0.1 to 0.7 ng/mg. CBD concentrations ranged from 0.7 to 14.1 ng/mg, and CBN concentrations ranged from 0.4 to 0.7 ng/mg. The effectiveness of different decontamination procedures was also studied on passively contaminated hair. The proposed method is also suitable for the analysis of methadone in hair; cocaine and cocaethylene can be detected in hair with SPME extraction after enzymatic hydrolysis.  (+info)

Acquisition of nicotine discrimination and discriminative stimulus effects of nicotine in rats chronically exposed to caffeine. (2/1361)

Caffeine and nicotine are the main psychoactive ingredients of coffee and tobacco, with a high frequency of concurrent use in humans. This study examined the effects of chronic caffeine exposure on 1) rates of acquisition of a nicotine discrimination (0.1 or 0.4 mg/kg, s.c., training doses) and 2) the pharmacological characteristics of the established nicotine discrimination in male Sprague-Dawley rats. Once rats learned to lever-press reliably under a fixed ratio of 10 schedule for food pellets, they were randomly divided into two groups; 12 animals were maintained continuously on caffeine added to the drinking water (3 mg/ml) and another 12 control rats continued to drink tap water. In each group of water- and caffeine-drinking rats, there were six rats trained to discriminate 0.1 mg/kg of nicotine from saline and six rats trained to discriminate 0.4 mg/kg of nicotine from saline. Regardless of the training dose of nicotine, both water- and caffeine-drinking groups required a comparable number of training sessions to attain reliable stimulus control, although there was a trend for a slower acquisition in the caffeine-drinking group trained with 0.1 mg/kg of nicotine. Tests for generalization to different doses of nicotine revealed no significant differences in potency of nicotine between water- and caffeine-drinking groups. The nicotinic-receptor antagonist mecamylamine blocked the discriminative effects of 0.1 and 0.4 mg/kg nicotine with comparable potency and efficacy in water- and caffeine-drinking groups. There was a dose-related generalization to both the 0.1 and 0.4 mg/kg nicotine cue (maximum average of 51-83%) in water-drinking rats after i.p. treatment with d-amphetamine, cocaine, the selective dopamine uptake inhibitor GBR-12909, apomorphine, and the selective dopamine D1 receptor agonist SKF-82958, but not in caffeine-drinking rats (0-22%). There was no generalization to the nicotine cues after i.p. treatment with caffeine or the selective D2 (NPA) and D3 (PD 128,907) dopamine-receptor agonists in water- and caffeine-drinking rats. The dopamine-release inhibitor CGS 10746B reduced the discriminative effects of 0.4 mg/kg nicotine in water-drinking rats, but not in caffeine-drinking rats. There was no evidence of development of tolerance or sensitization to nicotine's effects throughout the study. In conclusion, chronic caffeine exposure (average, 135 mg/kg/day) did not affect the rate of acquisition of the nicotine discrimination, but it did reduce the dopaminergic component of the nicotine-discriminative cue. The reduction of the dopaminergic component of the nicotine cue was permanent, as this effect was still evident after the caffeine solution was replaced with water in caffeine-drinking rats. That nicotine could reliably serve as a discriminative stimulus in the absence of the dopaminergic component of its discriminative cue may differentiate nicotine from "classical dopaminergic" drugs of abuse such as cocaine and amphetamine.  (+info)

Age-related reductions in [3H]WIN 35,428 binding to the dopamine transporter in nigrostriatal and mesolimbic brain regions of the fischer 344 rat. (3/1361)

In the present study, we used the potent cocaine analog [3H]WIN 35, 428 to map and quantify binding to the dopamine transporter (DAT) within the dorsal striatum, nucleus accumbens, substantia nigra, and ventral tegmental area in young (6-month-old), middle-aged (12-month-old), and aged (18- and 24-month-old) Fischer 344 rats. Quantitative autoradiographic analysis of indirect [3H]WIN 35,428 saturation curves revealed two-site binding for all four brain regions in every age group. The percentage of binding to the high- or low-affinity sites did not differ with age or region and was approximately 50%. However, significant age-related decreases in the overall density (Bmax) of [3H]WIN 35,428-binding sites were observed in the striatum, nucleus accumbens, substantia nigra, and ventral tegmental area. The Bmax within all brain regions declined by more than 15% every 6 months, with the Bmax in the aged (24-month-old) group being approximately half that measured in the young adult (6-month-old) group. Competition experiments indicated that nomifensine also exhibited two-site binding to the DAT in Fischer 344 rats. No consistent age-related differences in binding affinities were noted with either [3H]WIN 35,428 or nomifensine. Taken together, these results support the hypothesis that functional DATs within the nigrostriatal and mesolimbic systems are down-regulated with age, without changing their affinity for ligands.  (+info)

Characterization of [125I]RTI-121 binding to dopamine transporter in vitro. (4/1361)

AIM: To characterize the binding of [125I]3 beta-(4-iodophenyl) tropane-2 beta-carboxylic acid isopropyl ester (RTI-121) to the dopamine transporter (DAT) under physiologically relevant conditions. METHODS: [125I]RTI-121 was used to label the DAT on fresh rat striatum synaptosomal membranes in artificial cerebrospinal fluid (ACSF) at 37 degrees C. RESULTS: [125I]RTI-121 binding reached equilibrium within 3 min and remained at its plateau value for at least 9 min. The data from kinetic, saturation, and competition studies supported a one-site model for the binding of [125I]RTI-121 to the DAT. Various DAT blockers (oocaine, GBR12935, and BTCP) and substrates (dopamine and d-amphetamine) competitively inhibited the binding of [125I]RTI-121. Compared with NaPhos-KCl-NaCl assay buffer, ACSF containing Ca2+ and Mg2+ markedly increased the IC50 of DAT blockers for inhibiting [125I]RTI-121 binding with less effect on that of substrates. Various D2 receptor ligands (pergolide, quinirole, sulpiride, and l-stepholidine) had no direct effect on the binding of [125I]RTI-121. CONCLUSION: [125I]RTI-121 binding under physiologically relevant conditions fulfills the basic criteria for DAT binding assay.  (+info)

ATP-sensitive potassium channels regulate in vivo dopamine release in rat striatum. (5/1361)

ATP-sensitive K+ channels (K(ATP)) are distributed in a variety of tissues including smooth muscle, cardiac and skeletal muscle, pancreatic beta-cells and neurons. Since K(ATP) channels are present in the nigrostriatal dopamine (DA) pathway, the effect of potassium-channel modulators on the release of DA in the striatum of conscious, freely-moving rats was investigated. The extracellular concentration of DA was significantly decreased by the K(ATP)-channel opener (-)-cromakalim but not by diazoxide. (-)-Cromakalim was effective at 100 and 1000 microM concentrations, and the maximum decrease was 54% below baseline. d-Amphetamine significantly increased extracellular DA levels at the doses of 0.75 and 1.5 mg/kg, s.c. with a 770% maximum increase. (-)-Cromakalim had no effect on d-amphetamine-induced DA release, while glyburide, a K(ATP) blocker, significantly potentiated the effects of a low dose of d-amphetamine. These data indicate that K+ channels present in the nigrostriatal dopaminergic terminals modulate basal release as well as evoked release of DA.  (+info)

Comparison of effects of haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum. (6/1361)

Research has shown that there are important neurochemical differences between the mesocortical and mesostriatal dopamine systems. The work reported in this paper has sought to compare the regulation of dopamine release in the medial prefrontal cortex and the anterior caudate-putamen. In vivo microdialysis was used to recover dialysate fluid for subsequent assay for dopamine concentrations. The responses to D2 antagonist (haloperidol) administration, which has been shown to increase impulse-dependent dopamine release, were compared. Results demonstrated a diminished effect of systemic haloperidol administration on dopamine efflux in the prefrontal cortex. The responses to systemic administration of a nonimpulse-dependent, transporter-mediated, dopamine releaser (d-amphetamine) were also contrasted. Results again demonstrated a diminished pharmacological effect in the cortex. The potential interaction of stimulation of these two types of dopamine release was examined by coadministration of these compounds. Haloperidol pretreatment dramatically potentiated the dopamine-releasing effect of amphetamine administration. This effect was observed in both the cortex and the striatum. Subsequent work demonstrated that this effect of haloperidol was mediated by D2-like receptors in the prefrontal cortex. These results are discussed in relation to other neurochemical and neuroanatomical studies demonstrating sparse densities of dopamine transporter sites and dopamine D2 receptors in the cortex compared with the striatum. They demonstrate a functional correlate to the recently reported, largely extrasynaptic localization of dopamine transporter sites in the prefrontal cortex. Furthermore, they demonstrate the existence of cortical D2-like autoreceptors that may normally be "silent" under basal conditions.  (+info)

Female gonadal hormones differentially modulate cocaine-induced behavioral sensitization in Fischer, Lewis, and Sprague-Dawley rats. (7/1361)

Evidence suggests the existence of genetic differences in cocaine sensitization in male rats. The present study was undertaken to investigate cocaine sensitization in female rats of genetically distinct inbred (Fischer 344 and Lewis) and outbred (Sprague-Dawley) strains. All female rats were bilaterally ovariectomized and randomly assigned to one of four experimental groups: 1) estradiol benzoate group, 2) progesterone group, 3) estradiol benzoate-plus-progesterone group, and 4) ovariectomized group. Additional controls included sham-operated female rats, female rats that received a single oil injection, and female rats that received repeated oil injections. To determine gender-related differences in the acute and chronic effects of cocaine, data obtained from female rats were compared with those from strain- and weight-matched male rats. Estradiol benzoate-plus-progesterone female rats showed greater locomotor effect in response to an acute dose of cocaine and had more robust sensitization in response to repeated cocaine than did male rats. The bilateral removal of ovaries abolished cocaine sensitization. In all strains of rats studied, progesterone alone did not alter the ovariectomy-induced attenuation of cocaine behavior, but estrogen alone restored cocaine-induced behavioral sensitization. There were significant strain effects on the degree of gonadal hormonal-induced modulation of cocaine sensitization in female rats. Female Lewis rats were extremely sensitive to repeated-cocaine effects, whereas the Fischer 344 female rats showed only marginal effects. The Sprague-Dawley rats ranked intermediate in their behavioral sensitivity. The present study strongly supports the hypothesis that female rats are more sensitive to both acute and chronic behavioral effects of cocaine than are male rats and that the effects are strain dependent. It also shows that estrogen plays an important role in the increased sensitivity of female rats to cocaine sensitization. Together, these data indicate significant interactions between ovarian steroid hormones and genetic factors in cocaine-induced behavioral effects.  (+info)

Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo. (8/1361)

The current studies evaluated the novel diphenylmethoxytropane analog 4-chlorobenztropine (4-Cl-BZT), cocaine, and combinations of the two drugs for their abilities to stimulate locomotor activity, produce cocaine-like discriminative stimulus effects, and elevate extracellular dopamine (DA) in the nucleus accumbens (NAc) as measured by in vivo microdialysis. Peripherally administered cocaine was approximately twice as efficacious as 4-Cl-BZT as a locomotor stimulant and was behaviorally active at a lower dose than was 4-Cl-BZT. Cocaine also was more efficacious than 4-Cl-BZT in producing discriminative-stimulus effects in rats trained to discriminate i.p. injections of 10 mg/kg cocaine from saline. The time course of behavioral activation differed markedly between the two drugs, with much shorter onset and duration of locomotor stimulant effects for cocaine relative to 4-Cl-BZT. Similarly, i.p. cocaine (10 and 40 mg/kg) induced a pronounced, rapid, and short-lived increase in DA in the NAc, whereas i.p. 4-Cl-BZT was effective only at the higher dose and produced a more gradual, modest, and sustained (>/=2 h) elevation in accumbens DA. In contrast to i.p. administration, local infusion of 4-Cl-BZT (1-100 microM) into the NAc through the microdialysis probe elevated extracellular DA to a much greater extent than did local cocaine (nearly 2000% of baseline maximally for 4-Cl-BZT versus 400% of baseline for cocaine) and displayed a much longer duration of action than cocaine. However, when microinjected bilaterally into the NAc at 30 or 300 nmol/side, cocaine remained a more efficacious locomotor stimulant than 4-Cl-BZT. Finally, pretreatment with i.p. 4-Cl-BZT dose dependently enhanced the locomotor stimulant, discriminative stimulus effects, and NAc DA response to a subsequent low-dose i.p. cocaine challenge. The diphenylmethoxytropane analog also facilitated the emergence of stereotyped behavior and convulsions induced by high-dose cocaine. The current results demonstrate that DA transporter ligands that do not share the neurochemical and behavioral profiles of cocaine nevertheless may enhance the effects of cocaine in vivo.  (+info)

Dopamine uptake inhibitors are a class of medications that work by blocking the reuptake of dopamine, a neurotransmitter, into the presynaptic neuron. This results in an increased concentration of dopamine in the synapse, leading to enhanced dopaminergic transmission and activity.

These drugs are used in various medical conditions where dopamine is implicated, such as depression, attention deficit hyperactivity disorder (ADHD), and neurological disorders like Parkinson's disease. They can also be used to treat substance abuse disorders, such as cocaine addiction, by blocking the reuptake of dopamine and reducing the rewarding effects of the drug.

Examples of dopamine uptake inhibitors include:

* Bupropion (Wellbutrin), which is used to treat depression and ADHD
* Methylphenidate (Ritalin, Concerta), which is used to treat ADHD
* Amantadine (Symmetrel), which is used to treat Parkinson's disease and also has antiviral properties.

It's important to note that dopamine uptake inhibitors can have side effects, including increased heart rate, blood pressure, and anxiety. They may also have the potential for abuse and dependence, particularly in individuals with a history of substance abuse. Therefore, these medications should be used under the close supervision of a healthcare provider.

Benztropine is an anticholinergic medication that is primarily used to treat the symptoms of Parkinson's disease, such as rigidity, tremors, and muscle spasms. It works by blocking the action of acetylcholine, a neurotransmitter in the brain that is involved in the regulation of motor function.

Benztropine is also used to treat side effects caused by certain medications, such as antipsychotics, that can cause Parkinson-like symptoms. It may be prescribed to help reduce drooling or to manage muscle stiffness and restlessness.

The medication comes in the form of tablets or a solution for injection and is typically taken orally once or twice a day. Common side effects of benztropine include dry mouth, blurred vision, dizziness, and constipation. More serious side effects may include hallucinations, confusion, and irregular heartbeat.

It's important to note that benztropine can interact with other medications, so it's essential to inform your healthcare provider of all the drugs you are taking before starting this medication. Additionally, benztropine should be used cautiously in older adults, people with glaucoma or enlarged prostate, and those with a history of heart problems.

Nomifensine is a medication that was previously used in the treatment of depression, but it is no longer available in many countries due to safety concerns. It is a non-tricyclic antidepressant that works by inhibiting the reuptake of dopamine and noradrenaline, which helps to increase the levels of these neurotransmitters in the brain and improve mood.

The medical definition of Nomifensine is:

"Nomifensine is a non-tricyclic antidepressant that is a potent inhibitor of dopamine and noradrenaline reuptake, with minimal effects on serotonin reuptake. It was used in the treatment of depression but has been withdrawn from the market due to safety concerns."

It's important to note that Nomifensine should only be taken under the supervision of a medical professional, and it is not available in many countries due to its potential for causing serious side effects such as liver toxicity and the risk of developing a rare but potentially fatal condition called hemolytic anemia.

Dopamine is a type of neurotransmitter, which is a chemical messenger that transmits signals in the brain and nervous system. It plays several important roles in the body, including:

* Regulation of movement and coordination
* Modulation of mood and motivation
* Control of the reward and pleasure centers of the brain
* Regulation of muscle tone
* Involvement in memory and attention

Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. It is released by neurons (nerve cells) and binds to specific receptors on other neurons, where it can either excite or inhibit their activity.

Abnormalities in dopamine signaling have been implicated in several neurological and psychiatric conditions, including Parkinson's disease, schizophrenia, and addiction.

Cocaine is a highly addictive stimulant drug derived from the leaves of the coca plant (Erythroxylon coca). It is a powerful central nervous system stimulant that affects the brain and body in many ways. When used recreationally, cocaine can produce feelings of euphoria, increased energy, and mental alertness; however, it can also cause serious negative consequences, including addiction, cardiovascular problems, seizures, and death.

Cocaine works by increasing the levels of dopamine in the brain, a neurotransmitter associated with pleasure and reward. This leads to the pleasurable effects that users seek when they take the drug. However, cocaine also interferes with the normal functioning of the brain's reward system, making it difficult for users to experience pleasure from natural rewards like food or social interactions.

Cocaine can be taken in several forms, including powdered form (which is usually snorted), freebase (a purer form that is often smoked), and crack cocaine (a solid form that is typically heated and smoked). Each form of cocaine has different risks and potential harms associated with its use.

Long-term use of cocaine can lead to a number of negative health consequences, including addiction, heart problems, malnutrition, respiratory issues, and mental health disorders like depression or anxiety. It is important to seek help if you or someone you know is struggling with cocaine use or addiction.

Neurotransmitter uptake inhibitors are a class of drugs that work by blocking the reuptake of neurotransmitters, such as serotonin, norepinephrine, and dopamine, into the presynaptic neuron after they have been released into the synapse. This results in an increased concentration of these neurotransmitters in the synapse, which can enhance their signal transduction and lead to therapeutic effects.

These drugs are commonly used in the treatment of various psychiatric disorders, such as depression, anxiety, and attention deficit hyperactivity disorder (ADHD). They include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and norepinephrine reuptake inhibitors (NRIs).

It's important to note that while neurotransmitter uptake inhibitors can be effective in treating certain conditions, they may also have potential side effects and risks. Therefore, it is essential to use them under the guidance and supervision of a healthcare professional.

Dopamine plasma membrane transport proteins, also known as dopamine transporters (DAT), are a type of protein found in the cell membrane that play a crucial role in the regulation of dopamine neurotransmission. They are responsible for the reuptake of dopamine from the synaptic cleft back into the presynaptic neuron, thereby terminating the signal transduction of dopamine and regulating the amount of dopamine available for further release.

Dopamine transporters belong to the family of sodium-dependent neurotransmitter transporters and are encoded by the SLC6A3 gene in humans. Abnormalities in dopamine transporter function have been implicated in several neurological and psychiatric disorders, including Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and substance use disorders.

In summary, dopamine plasma membrane transport proteins are essential for the regulation of dopamine neurotransmission by mediating the reuptake of dopamine from the synaptic cleft back into the presynaptic neuron.

Piperazines are a class of heterocyclic organic compounds that contain a seven-membered ring with two nitrogen atoms at positions 1 and 4. They have the molecular formula N-NRR' where R and R' can be alkyl or aryl groups. Piperazines have a wide range of uses in pharmaceuticals, agrochemicals, and as building blocks in organic synthesis.

In a medical context, piperazines are used in the manufacture of various drugs, including some antipsychotics, antidepressants, antihistamines, and anti-worm medications. For example, the antipsychotic drug trifluoperazine and the antidepressant drug nefazodone both contain a piperazine ring in their chemical structure.

However, it's important to note that some piperazines are also used as recreational drugs due to their stimulant and euphoric effects. These include compounds such as BZP (benzylpiperazine) and TFMPP (trifluoromethylphenylpiperazine), which have been linked to serious health risks, including addiction, seizures, and death. Therefore, the use of these substances should be avoided.

Dopamine D2 receptor is a type of metabotropic G protein-coupled receptor that binds to the neurotransmitter dopamine. It is one of five subtypes of dopamine receptors (D1-D5) and is encoded by the gene DRD2. The activation of D2 receptors leads to a decrease in the activity of adenylyl cyclase, which results in reduced levels of cAMP and modulation of ion channels.

D2 receptors are widely distributed throughout the central nervous system (CNS) and play important roles in various physiological functions, including motor control, reward processing, emotion regulation, and cognition. They are also involved in several neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, drug addiction, and Tourette syndrome.

D2 receptors have two main subtypes: D2 short (D2S) and D2 long (D2L). The D2S subtype is primarily located in the presynaptic terminals and functions as an autoreceptor that regulates dopamine release, while the D2L subtype is mainly found in the postsynaptic neurons and modulates intracellular signaling pathways.

Antipsychotic drugs, which are used to treat schizophrenia and other psychiatric disorders, work by blocking D2 receptors. However, excessive blockade of these receptors can lead to side effects such as extrapyramidal symptoms (EPS), tardive dyskinesia, and hyperprolactinemia. Therefore, the development of drugs that selectively target specific subtypes of dopamine receptors is an active area of research in the field of neuropsychopharmacology.

Mazindol is a prescription medication that belongs to a class of drugs known as sympathomimetic amines or anorectics. It has been used in the treatment of obesity, as it works by reducing appetite and increasing the amount of energy that the body uses. Mazindol affects certain chemicals in the brain that control appetite.

It's important to note that mazindol is not commonly used today due to its potential for abuse and serious side effects. It should only be used under the close supervision of a healthcare provider, and its use is typically reserved for individuals with severe obesity who have not responded to other treatment options.

Dopamine antagonists are a class of drugs that block the action of dopamine, a neurotransmitter in the brain associated with various functions including movement, motivation, and emotion. These drugs work by binding to dopamine receptors and preventing dopamine from attaching to them, which can help to reduce the symptoms of certain medical conditions such as schizophrenia, bipolar disorder, and gastroesophageal reflux disease (GERD).

There are several types of dopamine antagonists, including:

1. Typical antipsychotics: These drugs are primarily used to treat psychosis, including schizophrenia and delusional disorders. Examples include haloperidol, chlorpromazine, and fluphenazine.
2. Atypical antipsychotics: These drugs are also used to treat psychosis but have fewer side effects than typical antipsychotics. They may also be used to treat bipolar disorder and depression. Examples include risperidone, olanzapine, and quetiapine.
3. Antiemetics: These drugs are used to treat nausea and vomiting. Examples include metoclopramide and prochlorperazine.
4. Dopamine agonists: While not technically dopamine antagonists, these drugs work by stimulating dopamine receptors and can be used to treat conditions such as Parkinson's disease. However, they can also have the opposite effect and block dopamine receptors in high doses, making them functionally similar to dopamine antagonists.

Common side effects of dopamine antagonists include sedation, weight gain, and movement disorders such as tardive dyskinesia. It's important to use these drugs under the close supervision of a healthcare provider to monitor for side effects and adjust the dosage as needed.

Dopamine receptors are a type of G protein-coupled receptor that bind to and respond to the neurotransmitter dopamine. There are five subtypes of dopamine receptors (D1-D5), which are classified into two families based on their structure and function: D1-like (D1 and D5) and D2-like (D2, D3, and D4).

Dopamine receptors play a crucial role in various physiological processes, including movement, motivation, reward, cognition, emotion, and neuroendocrine regulation. They are widely distributed throughout the central nervous system, with high concentrations found in the basal ganglia, limbic system, and cortex.

Dysfunction of dopamine receptors has been implicated in several neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), drug addiction, and depression. Therefore, drugs targeting dopamine receptors have been developed for the treatment of these conditions.

Dopamine D1 receptors are a type of G protein-coupled receptor that bind to the neurotransmitter dopamine. They are classified as D1-like receptors, along with D5 receptors, and are activated by dopamine through a stimulatory G protein (Gs).

D1 receptors are widely expressed in the central nervous system, including the striatum, prefrontal cortex, hippocampus, and amygdala. They play important roles in various physiological functions, such as movement control, motivation, reward processing, working memory, and cognition.

Activation of D1 receptors leads to increased levels of intracellular cyclic adenosine monophosphate (cAMP) and activation of protein kinase A (PKA), which in turn modulate the activity of various downstream signaling pathways. Dysregulation of dopamine D1 receptor function has been implicated in several neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), and drug addiction.

Dopamine agonists are a class of medications that mimic the action of dopamine, a neurotransmitter in the brain that regulates movement, emotion, motivation, and reinforcement of rewarding behaviors. These medications bind to dopamine receptors in the brain and activate them, leading to an increase in dopaminergic activity.

Dopamine agonists are used primarily to treat Parkinson's disease, a neurological disorder characterized by motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. By increasing dopaminergic activity in the brain, dopamine agonists can help alleviate some of these symptoms.

Examples of dopamine agonists include:

1. Pramipexole (Mirapex)
2. Ropinirole (Requip)
3. Rotigotine (Neupro)
4. Apomorphine (Apokyn)

Dopamine agonists may also be used off-label to treat other conditions, such as restless legs syndrome or certain types of dopamine-responsive dystonia. However, these medications can have significant side effects, including nausea, dizziness, orthostatic hypotension, compulsive behaviors (such as gambling, shopping, or sexual addiction), and hallucinations. Therefore, they should be used with caution and under the close supervision of a healthcare provider.

Adrenergic uptake inhibitors are a class of medications that work by blocking the reuptake of neurotransmitters, such as norepinephrine and dopamine, into the presynaptic neuron. This results in an increase in the amount of neurotransmitter available to bind to postsynaptic receptors, leading to an enhancement of adrenergic transmission.

These medications are used in the treatment of various medical conditions, including depression, attention deficit hyperactivity disorder (ADHD), and narcolepsy. Some examples of adrenergic uptake inhibitors include:

* Tricyclic antidepressants (TCAs): These medications, such as imipramine and amitriptyline, were developed in the 1950s and are used to treat depression, anxiety disorders, and chronic pain.
* Selective serotonin-norepinephrine reuptake inhibitors (SNRIs): These medications, such as venlafaxine and duloxetine, were developed in the 1990s and are used to treat depression, anxiety disorders, and chronic pain.
* Norepinephrine-dopamine reuptake inhibitors (NDRIs): These medications, such as bupropion, are used to treat depression and ADHD.

It's important to note that these medications can have side effects and should be used under the supervision of a healthcare provider.

Synaptosomes are subcellular structures that can be isolated from the brain tissue. They are formed during the fractionation process of brain homogenates and consist of intact presynaptic terminals, including the synaptic vesicles, mitochondria, and cytoskeletal elements. Synaptosomes are often used in neuroscience research to study the biochemical properties and functions of neuronal synapses, such as neurotransmitter release, uptake, and metabolism.

Dopamine D3 receptors are a type of G protein-coupled receptor that bind to the neurotransmitter dopamine. They are classified as part of the D2-like family of dopamine receptors, which also includes the D2 and D4 receptors. The D3 receptor is primarily expressed in the limbic areas of the brain, including the hippocampus and the nucleus accumbens, where it plays a role in regulating motivation, reward, and cognition.

D3 receptors have been found to be involved in several neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, and drug addiction. In Parkinson's disease, the loss of dopamine-producing neurons in the substantia nigra results in a decrease in dopamine levels and an increase in D3 receptor expression. This increase in D3 receptor expression has been linked to the development of motor symptoms such as bradykinesia and rigidity.

In schizophrenia, antipsychotic medications that block D2-like receptors, including D3 receptors, are used to treat positive symptoms such as hallucinations and delusions. However, selective D3 receptor antagonists have also been shown to have potential therapeutic effects in treating negative symptoms of schizophrenia, such as apathy and anhedonia.

In drug addiction, D3 receptors have been found to play a role in the rewarding effects of drugs of abuse, such as cocaine and amphetamines. Selective D3 receptor antagonists have shown promise in reducing drug-seeking behavior and preventing relapse in animal models of addiction.

Overall, dopamine D3 receptors play an important role in several neurological and psychiatric disorders, and further research is needed to fully understand their functions and potential therapeutic uses.

The corpus striatum is a part of the brain that plays a crucial role in movement, learning, and cognition. It consists of two structures called the caudate nucleus and the putamen, which are surrounded by the external and internal segments of the globus pallidus. Together, these structures form the basal ganglia, a group of interconnected neurons that help regulate voluntary movement.

The corpus striatum receives input from various parts of the brain, including the cerebral cortex, thalamus, and other brainstem nuclei. It processes this information and sends output to the globus pallidus and substantia nigra, which then project to the thalamus and back to the cerebral cortex. This feedback loop helps coordinate and fine-tune movements, allowing for smooth and coordinated actions.

Damage to the corpus striatum can result in movement disorders such as Parkinson's disease, Huntington's disease, and dystonia. These conditions are characterized by abnormal involuntary movements, muscle stiffness, and difficulty initiating or controlling voluntary movements.

GABA (gamma-aminobutyric acid) uptake inhibitors are a class of drugs or compounds that block the reuptake of GABA, an inhibitory neurotransmitter in the brain, into the presynaptic neuron. By blocking the reuptake, GABA uptake inhibitors increase the concentration of GABA in the synaptic cleft, which can enhance its inhibitory effects on neural activity. These drugs are sometimes used in the treatment of various neurological and psychiatric conditions, such as anxiety disorders, epilepsy, and spasticity. Examples of GABA uptake inhibitors include tiagabine and vigabatrin.

Tropane alkaloids are a class of naturally occurring compounds that contain a tropane ring in their chemical structure. This ring is composed of a seven-membered ring with two nitrogen atoms, one of which is part of a piperidine ring. Tropane alkaloids are found in various plants, particularly those in the Solanaceae family, which includes nightshade, belladonna, and datura. Some well-known tropane alkaloids include atropine, scopolamine, and cocaine. These compounds have diverse pharmacological activities, such as anticholinergic, local anesthetic, and central nervous system stimulant effects.

Membrane transport proteins are specialized biological molecules, specifically integral membrane proteins, that facilitate the movement of various substances across the lipid bilayer of cell membranes. They are responsible for the selective and regulated transport of ions, sugars, amino acids, nucleotides, and other molecules into and out of cells, as well as within different cellular compartments. These proteins can be categorized into two main types: channels and carriers (or pumps). Channels provide a passive transport mechanism, allowing ions or small molecules to move down their electrochemical gradient, while carriers actively transport substances against their concentration gradient, requiring energy usually in the form of ATP. Membrane transport proteins play a crucial role in maintaining cell homeostasis, signaling processes, and many other physiological functions.

Norepinephrine plasma membrane transport proteins, also known as norepinephrine transporters (NET), are membrane-bound proteins that play a crucial role in the regulation of neurotransmission. They are responsible for the reuptake of norepinephrine from the synaptic cleft back into the presynaptic neuron, thereby terminating the signal transmission and preventing excessive stimulation of postsynaptic receptors.

The norepinephrine transporter is a member of the sodium-dependent neurotransmitter transporter family and functions as an antiporter, exchanging one intracellular sodium ion for two extracellular sodium ions along with the transport of norepinephrine. This sodium gradient provides the energy required for the active transport process.

Dysregulation of norepinephrine plasma membrane transport proteins has been implicated in various neurological and psychiatric disorders, such as attention deficit hyperactivity disorder (ADHD), depression, and post-traumatic stress disorder (PTSD). Therefore, understanding the function and regulation of these transporters is essential for developing novel therapeutic strategies to treat these conditions.

The nucleus accumbens is a part of the brain that is located in the ventral striatum, which is a key region of the reward circuitry. It is made up of two subregions: the shell and the core. The nucleus accumbens receives inputs from various sources, including the prefrontal cortex, amygdala, and hippocampus, and sends outputs to the ventral pallidum and other areas.

The nucleus accumbens is involved in reward processing, motivation, reinforcement learning, and addiction. It plays a crucial role in the release of the neurotransmitter dopamine, which is associated with pleasure and reinforcement. Dysfunction in the nucleus accumbens has been implicated in various neurological and psychiatric conditions, including substance use disorders, depression, and obsessive-compulsive disorder.

Sprague-Dawley rats are a strain of albino laboratory rats that are widely used in scientific research. They were first developed by researchers H.H. Sprague and R.C. Dawley in the early 20th century, and have since become one of the most commonly used rat strains in biomedical research due to their relatively large size, ease of handling, and consistent genetic background.

Sprague-Dawley rats are outbred, which means that they are genetically diverse and do not suffer from the same limitations as inbred strains, which can have reduced fertility and increased susceptibility to certain diseases. They are also characterized by their docile nature and low levels of aggression, making them easier to handle and study than some other rat strains.

These rats are used in a wide variety of research areas, including toxicology, pharmacology, nutrition, cancer, and behavioral studies. Because they are genetically diverse, Sprague-Dawley rats can be used to model a range of human diseases and conditions, making them an important tool in the development of new drugs and therapies.

Serotonin, also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter that is found primarily in the gastrointestinal (GI) tract, blood platelets, and the central nervous system (CNS) of humans and other animals. It is produced by the conversion of the amino acid tryptophan to 5-hydroxytryptophan (5-HTP), and then to serotonin.

In the CNS, serotonin plays a role in regulating mood, appetite, sleep, memory, learning, and behavior, among other functions. It also acts as a vasoconstrictor, helping to regulate blood flow and blood pressure. In the GI tract, it is involved in peristalsis, the contraction and relaxation of muscles that moves food through the digestive system.

Serotonin is synthesized and stored in serotonergic neurons, which are nerve cells that use serotonin as their primary neurotransmitter. These neurons are found throughout the brain and spinal cord, and they communicate with other neurons by releasing serotonin into the synapse, the small gap between two neurons.

Abnormal levels of serotonin have been linked to a variety of disorders, including depression, anxiety, schizophrenia, and migraines. Medications that affect serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs), are commonly used to treat these conditions.

Dopamine agents are medications that act on dopamine receptors in the brain. Dopamine is a neurotransmitter, a chemical messenger that transmits signals in the brain and other areas of the body. It plays important roles in many functions, including movement, motivation, emotion, and cognition.

Dopamine agents can be classified into several categories based on their mechanism of action:

1. Dopamine agonists: These medications bind to dopamine receptors and mimic the effects of dopamine. They are used to treat conditions such as Parkinson's disease, restless legs syndrome, and certain types of dopamine-responsive dystonia. Examples include pramipexole, ropinirole, and rotigotine.
2. Dopamine precursors: These medications provide the building blocks for the body to produce dopamine. Levodopa is a commonly used dopamine precursor that is converted to dopamine in the brain. It is often used in combination with carbidopa, which helps to prevent levodopa from being broken down before it reaches the brain.
3. Dopamine antagonists: These medications block the action of dopamine at its receptors. They are used to treat conditions such as schizophrenia and certain types of nausea and vomiting. Examples include haloperidol, risperidone, and metoclopramide.
4. Dopamine reuptake inhibitors: These medications increase the amount of dopamine available in the synapse (the space between two neurons) by preventing its reuptake into the presynaptic neuron. They are used to treat conditions such as attention deficit hyperactivity disorder (ADHD) and depression. Examples include bupropion and nomifensine.
5. Dopamine release inhibitors: These medications prevent the release of dopamine from presynaptic neurons. They are used to treat conditions such as Tourette's syndrome and certain types of chronic pain. Examples include tetrabenazine and deutetrabenazine.

It is important to note that dopamine agents can have significant side effects, including addiction, movement disorders, and psychiatric symptoms. Therefore, they should be used under the close supervision of a healthcare provider.

Zimeldine is not commonly used in current medical practice due to its association with serious side effects. However, historically, it was a medication used as an antidepressant. It belongs to the class of drugs called selective serotonin reuptake inhibitors (SSRIs), which work by increasing the levels of the neurotransmitter serotonin in the brain.

Zimeldine was first synthesized in 1972 and approved for medical use in Sweden in 1982. However, it was withdrawn from the market in 1983 due to its association with a rare but serious side effect called Guillain-Barré syndrome, which is a neurological disorder that can cause muscle weakness and paralysis.

Although Zimeldine is no longer used in medical practice, it played an important role in the development of SSRIs as a class of antidepressants, which have since become widely used due to their effectiveness and relatively favorable side effect profile compared to earlier classes of antidepressants.

Nipecotic acids are a class of compounds that function as GABA transaminase inhibitors. GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the central nervous system, and its levels are regulated by enzymes such as GABA transaminase.

Nipecotic acids work by inhibiting this enzyme, leading to an increase in GABA levels in the brain. This can have various effects on the nervous system, including sedative, hypnotic, and anticonvulsant actions. Some nipecotic acid derivatives are used in research as tools for studying the role of GABA in the brain, while others have been investigated for their potential therapeutic uses in treating conditions such as anxiety, insomnia, and epilepsy.

It's important to note that nipecotic acids and their derivatives can have significant side effects and toxicity, and they are not approved for use as medications in most countries. Therefore, they should only be used under the close supervision of a trained medical professional for research purposes.

Methamphetamine is a powerful, highly addictive central nervous system stimulant that affects brain chemistry, leading to mental and physical dependence. Its chemical formula is N-methylamphetamine, and it is structurally similar to amphetamine but has additional methyl group, which makes it more potent and longer-lasting.

Methamphetamine exists in various forms, including crystalline powder (commonly called "meth" or "crystal meth") and a rocklike form called "glass." It can be taken orally, snorted, smoked, or injected after being dissolved in water or alcohol.

Methamphetamine use leads to increased levels of dopamine, a neurotransmitter responsible for reward, motivation, and reinforcement, resulting in euphoria, alertness, and energy. Prolonged use can cause severe psychological and physiological harm, including addiction, psychosis, cardiovascular issues, dental problems (meth mouth), and cognitive impairments.

Desipramine is a tricyclic antidepressant (TCA) that is primarily used to treat depression. It works by increasing the levels of certain neurotransmitters, such as norepinephrine and serotonin, in the brain. These neurotransmitters are important for maintaining mood, emotion, and behavior.

Desipramine is also sometimes used off-label to treat other conditions, such as anxiety disorders, chronic pain, and attention deficit hyperactivity disorder (ADHD). It is available in oral form and is typically taken one to three times a day.

Like all medications, desipramine can cause side effects, which can include dry mouth, blurred vision, constipation, dizziness, and drowsiness. More serious side effects are rare but can include heart rhythm problems, seizures, and increased suicidal thoughts or behavior in some people, particularly children and adolescents.

It is important to take desipramine exactly as prescribed by a healthcare provider and to report any bothersome or unusual symptoms promptly. Regular follow-up appointments with a healthcare provider are also recommended to monitor the effectiveness and safety of the medication.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Serotonin uptake inhibitors (also known as Selective Serotonin Reuptake Inhibitors or SSRIs) are a class of medications primarily used to treat depression and anxiety disorders. They work by increasing the levels of serotonin, a neurotransmitter in the brain that helps regulate mood, appetite, and sleep, among other functions.

SSRIs block the reuptake of serotonin into the presynaptic neuron, allowing more serotonin to be available in the synapse (the space between two neurons) for binding to postsynaptic receptors. This results in increased serotonergic neurotransmission and improved mood regulation.

Examples of SSRIs include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), and escitalopram (Lexapro). These medications are generally well-tolerated, with side effects that may include nausea, headache, insomnia, sexual dysfunction, and increased anxiety or agitation. However, they can have serious interactions with other medications, so it is important to inform your healthcare provider of all medications you are taking before starting an SSRI.

The neostriatum is a component of the basal ganglia, a group of subcortical nuclei in the brain that are involved in motor control, procedural learning, and other cognitive functions. It is composed primarily of two types of neurons: medium spiny neurons and aspiny interneurons. The neostriatum receives input from various regions of the cerebral cortex and projects to other parts of the basal ganglia, forming an important part of the cortico-basal ganglia-thalamo-cortical loop.

In medical terminology, the neostriatum is often used interchangeably with the term "striatum," although some sources reserve the term "neostriatum" for the caudate nucleus and putamen specifically, while using "striatum" to refer to the entire structure including the ventral striatum (also known as the nucleus accumbens).

Damage to the neostriatum has been implicated in various neurological conditions, such as Huntington's disease and Parkinson's disease.

Microdialysis is a minimally invasive technique used in clinical and research settings to continuously monitor the concentration of various chemicals, such as neurotransmitters, drugs, or metabolites, in biological fluids (e.g., extracellular fluid of tissues, blood, or cerebrospinal fluid). This method involves inserting a small, flexible catheter with a semipermeable membrane into the region of interest. A physiological solution is continuously perfused through the catheter, allowing molecules to diffuse across the membrane based on their concentration gradient. The dialysate that exits the catheter is then collected and analyzed for target compounds using various analytical techniques (e.g., high-performance liquid chromatography, mass spectrometry).

In summary, microdialysis is a valuable tool for monitoring real-time changes in chemical concentrations within biological systems, enabling better understanding of physiological processes or pharmacokinetic properties of drugs.

Nerve tissue proteins are specialized proteins found in the nervous system that provide structural and functional support to nerve cells, also known as neurons. These proteins include:

1. Neurofilaments: These are type IV intermediate filaments that provide structural support to neurons and help maintain their shape and size. They are composed of three subunits - NFL (light), NFM (medium), and NFH (heavy).

2. Neuronal Cytoskeletal Proteins: These include tubulins, actins, and spectrins that provide structural support to the neuronal cytoskeleton and help maintain its integrity.

3. Neurotransmitter Receptors: These are specialized proteins located on the postsynaptic membrane of neurons that bind neurotransmitters released by presynaptic neurons, triggering a response in the target cell.

4. Ion Channels: These are transmembrane proteins that regulate the flow of ions across the neuronal membrane and play a crucial role in generating and transmitting electrical signals in neurons.

5. Signaling Proteins: These include enzymes, receptors, and adaptor proteins that mediate intracellular signaling pathways involved in neuronal development, differentiation, survival, and death.

6. Adhesion Proteins: These are cell surface proteins that mediate cell-cell and cell-matrix interactions, playing a crucial role in the formation and maintenance of neural circuits.

7. Extracellular Matrix Proteins: These include proteoglycans, laminins, and collagens that provide structural support to nerve tissue and regulate neuronal migration, differentiation, and survival.

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) medication that is primarily used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance.

Fluoxetine is available under the brand name Prozac and is also available as a generic medication. It comes in various forms, including capsules, tablets, delayed-release capsules, and liquid solution. The typical starting dose for adults with depression is 20 mg per day, but the dosage may be adjusted based on individual patient needs and response to treatment.

Fluoxetine has a relatively long half-life, which means it stays in the body for an extended period of time. This can be beneficial for patients who may have difficulty remembering to take their medication daily, as they may only need to take it once or twice a week. However, it also means that it may take several weeks for the full effects of the medication to become apparent.

As with any medication, fluoxetine can cause side effects, including nausea, dry mouth, sleepiness, insomnia, dizziness, and headache. In some cases, it may also increase the risk of suicidal thoughts or behavior in children, adolescents, and young adults, particularly during the initial stages of treatment. It is important for patients to discuss any concerns about side effects with their healthcare provider.

Norepinephrine, also known as noradrenaline, is a neurotransmitter and a hormone that is primarily produced in the adrenal glands and is released into the bloodstream in response to stress or physical activity. It plays a crucial role in the "fight-or-flight" response by preparing the body for action through increasing heart rate, blood pressure, respiratory rate, and glucose availability.

As a neurotransmitter, norepinephrine is involved in regulating various functions of the nervous system, including attention, perception, motivation, and arousal. It also plays a role in modulating pain perception and responding to stressful or emotional situations.

In medical settings, norepinephrine is used as a vasopressor medication to treat hypotension (low blood pressure) that can occur during septic shock, anesthesia, or other critical illnesses. It works by constricting blood vessels and increasing heart rate, which helps to improve blood pressure and perfusion of vital organs.

Dopamine D5 receptor is a type of dopamine receptor that belongs to the family of G protein-coupled receptors. It is also known as D5R or DRD5. These receptors are found in various parts of the brain, including the cortex and the hippocampus.

The activation of Dopamine D5 receptors leads to the stimulation of several intracellular signaling pathways, including the cAMP-dependent pathway, which results in the modulation of neuronal excitability, neurotransmitter release, and other cellular functions.

Dopamine D5 receptors have been implicated in various physiological processes, such as cognition, emotion, motor control, and reward processing. They have also been associated with several neurological and psychiatric disorders, including schizophrenia, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and drug addiction.

The medical definition of "Receptors, Dopamine D5" can be summarized as follows:

Dopamine D5 receptor is a type of G protein-coupled receptor that binds dopamine and activates several intracellular signaling pathways, leading to the modulation of various physiological processes. These receptors have been implicated in several neurological and psychiatric disorders and are a target for drug development.

Membrane glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. They are integral components of biological membranes, spanning the lipid bilayer and playing crucial roles in various cellular processes.

The glycosylation of these proteins occurs in the endoplasmic reticulum (ER) and Golgi apparatus during protein folding and trafficking. The attached glycans can vary in structure, length, and composition, which contributes to the diversity of membrane glycoproteins.

Membrane glycoproteins can be classified into two main types based on their orientation within the lipid bilayer:

1. Type I (N-linked): These glycoproteins have a single transmembrane domain and an extracellular N-terminus, where the oligosaccharides are predominantly attached via asparagine residues (Asn-X-Ser/Thr sequon).
2. Type II (C-linked): These glycoproteins possess two transmembrane domains and an intracellular C-terminus, with the oligosaccharides linked to tryptophan residues via a mannose moiety.

Membrane glycoproteins are involved in various cellular functions, such as:

* Cell adhesion and recognition
* Receptor-mediated signal transduction
* Enzymatic catalysis
* Transport of molecules across membranes
* Cell-cell communication
* Immunological responses

Some examples of membrane glycoproteins include cell surface receptors (e.g., growth factor receptors, cytokine receptors), adhesion molecules (e.g., integrins, cadherins), and transporters (e.g., ion channels, ABC transporters).

"Motor activity" is a general term used in the field of medicine and neuroscience to refer to any kind of physical movement or action that is generated by the body's motor system. The motor system includes the brain, spinal cord, nerves, and muscles that work together to produce movements such as walking, talking, reaching for an object, or even subtle actions like moving your eyes.

Motor activity can be voluntary, meaning it is initiated intentionally by the individual, or involuntary, meaning it is triggered automatically by the nervous system without conscious control. Examples of voluntary motor activity include deliberately lifting your arm or kicking a ball, while examples of involuntary motor activity include heartbeat, digestion, and reflex actions like jerking your hand away from a hot stove.

Abnormalities in motor activity can be a sign of neurological or muscular disorders, such as Parkinson's disease, cerebral palsy, or multiple sclerosis. Assessment of motor activity is often used in the diagnosis and treatment of these conditions.

Amphetamine is a central nervous system stimulant drug that works by increasing the levels of certain neurotransmitters (chemical messengers) in the brain, such as dopamine and norepinephrine. It is used medically to treat conditions such as attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity, due to its appetite-suppressing effects.

Amphetamines can be prescribed in various forms, including tablets, capsules, or liquids, and are available under several brand names, such as Adderall, Dexedrine, and Vyvanse. They are also known by their street names, such as speed, uppers, or wake-ups, and can be abused for their euphoric effects and ability to increase alertness, energy, and concentration.

Long-term use of amphetamines can lead to dependence, tolerance, and addiction, as well as serious health consequences, such as cardiovascular problems, mental health disorders, and malnutrition. It is essential to use amphetamines only under the supervision of a healthcare provider and follow their instructions carefully.

Lobeline is not a medical term per se, but it is a pharmacological substance with some potential medical applications. Lobeline is an alkaloid compound that can be found in certain plants, including the Indian tobacco plant (Lobelia inflata). It has been used in some over-the-counter and prescription medications as a smoking cessation aid due to its ability to stimulate nicotinic acetylcholine receptors in the brain, which may help reduce cravings for nicotine.

However, it's important to note that the effectiveness of lobeline as a smoking cessation aid is still a matter of debate and further research is needed to fully understand its potential benefits and risks.

'Animal behavior' refers to the actions or responses of animals to various stimuli, including their interactions with the environment and other individuals. It is the study of the actions of animals, whether they are instinctual, learned, or a combination of both. Animal behavior includes communication, mating, foraging, predator avoidance, and social organization, among other things. The scientific study of animal behavior is called ethology. This field seeks to understand the evolutionary basis for behaviors as well as their physiological and psychological mechanisms.

Methylphenidate is a central nervous system (CNS) stimulant drug that is primarily used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It works by increasing the levels of neurotransmitters, such as dopamine and norepinephrine, in the brain, which helps to improve focus, concentration, and alertness.

Methylphenidate is available under various brand names, including Ritalin, Concerta, and Methylin, among others. It comes in different forms, such as tablets, capsules, or extended-release formulations, and is typically taken orally. The dosage and duration of treatment are usually individualized based on the patient's response to the medication and any potential side effects.

It is important to note that methylphenidate has a high potential for abuse and addiction, and its use should be closely monitored by a healthcare professional. Additionally, it can interact with other medications and medical conditions, so it is essential to inform your doctor of any health concerns before starting treatment with methylphenidate.

The caudate nucleus is a part of the brain located within the basal ganglia, a group of structures that are important for movement control and cognition. It has a distinctive C-shaped appearance and plays a role in various functions such as learning, memory, emotion, and motivation. The caudate nucleus receives inputs from several areas of the cerebral cortex and sends outputs to other basal ganglia structures, contributing to the regulation of motor behavior and higher cognitive processes.

Biological transport refers to the movement of molecules, ions, or solutes across biological membranes or through cells in living organisms. This process is essential for maintaining homeostasis, regulating cellular functions, and enabling communication between cells. There are two main types of biological transport: passive transport and active transport.

Passive transport does not require the input of energy and includes:

1. Diffusion: The random movement of molecules from an area of high concentration to an area of low concentration until equilibrium is reached.
2. Osmosis: The diffusion of solvent molecules (usually water) across a semi-permeable membrane from an area of lower solute concentration to an area of higher solute concentration.
3. Facilitated diffusion: The assisted passage of polar or charged substances through protein channels or carriers in the cell membrane, which increases the rate of diffusion without consuming energy.

Active transport requires the input of energy (in the form of ATP) and includes:

1. Primary active transport: The direct use of ATP to move molecules against their concentration gradient, often driven by specific transport proteins called pumps.
2. Secondary active transport: The coupling of the movement of one substance down its electrochemical gradient with the uphill transport of another substance, mediated by a shared transport protein. This process is also known as co-transport or counter-transport.

Dopamine beta-hydroxylase (DBH) is an enzyme that plays a crucial role in the synthesis of catecholamines, which are important neurotransmitters and hormones in the human body. Specifically, DBH converts dopamine into norepinephrine, another essential catecholamine.

DBH is primarily located in the adrenal glands and nerve endings of the sympathetic nervous system. It requires molecular oxygen, copper ions, and vitamin C (ascorbic acid) as cofactors to perform its enzymatic function. Deficiency or dysfunction of DBH can lead to various medical conditions, such as orthostatic hypotension and neuropsychiatric disorders.

Vesicular Monoamine Transporter Proteins (VMATs) are a type of transmembrane protein that play a crucial role in the packaging and transport of monoamines, such as serotonin, dopamine, and norepinephrine, into synaptic vesicles within neurons. There are two main isoforms of VMATs, VMAT1 and VMAT2, which differ in their distribution and function.

VMAT1 (also known as SLC18A1) is primarily found in neuroendocrine cells and is responsible for transporting monoamines into large dense-core vesicles. VMAT2 (also known as SLC18A2), on the other hand, is mainly expressed in presynaptic neurons and is involved in the transport of monoamines into small synaptic vesicles.

Both VMAT1 and VMAT2 are integral membrane proteins that utilize a proton gradient to drive the uptake of monoamines against their concentration gradient, allowing for their storage and subsequent release during neurotransmission. Dysregulation of VMAT function has been implicated in several neurological and psychiatric disorders, including Parkinson's disease and depression.

Membrane transport modulators refer to a class of molecules that affect the movement of ions, nutrients, and other substances across cell membranes by interacting with membrane transport proteins. These proteins, also known as transporters or carriers, facilitate the passive or active transport of molecules in and out of cells.

Membrane transport modulators can either inhibit or enhance the activity of these transport proteins. They play a crucial role in pharmacology and therapeutics, as they can influence drug absorption, distribution, metabolism, and excretion (ADME). Examples of membrane transport modulators include ion channel blockers, inhibitors of efflux pumps like P-glycoprotein, and enhancers of nutrient uptake transporters.

It is important to note that the term "membrane transport modulator" can encompass a wide range of molecules with varying mechanisms and specificities, so further characterization is often necessary for a more precise understanding of their effects.

A drug interaction is the effect of combining two or more drugs, or a drug and another substance (such as food or alcohol), which can alter the effectiveness or side effects of one or both of the substances. These interactions can be categorized as follows:

1. Pharmacodynamic interactions: These occur when two or more drugs act on the same target organ or receptor, leading to an additive, synergistic, or antagonistic effect. For example, taking a sedative and an antihistamine together can result in increased drowsiness due to their combined depressant effects on the central nervous system.
2. Pharmacokinetic interactions: These occur when one drug affects the absorption, distribution, metabolism, or excretion of another drug. For example, taking certain antibiotics with grapefruit juice can increase the concentration of the antibiotic in the bloodstream, leading to potential toxicity.
3. Food-drug interactions: Some drugs may interact with specific foods, affecting their absorption, metabolism, or excretion. An example is the interaction between warfarin (a blood thinner) and green leafy vegetables, which can increase the risk of bleeding due to enhanced vitamin K absorption from the vegetables.
4. Drug-herb interactions: Some herbal supplements may interact with medications, leading to altered drug levels or increased side effects. For instance, St. John's Wort can decrease the effectiveness of certain antidepressants and oral contraceptives by inducing their metabolism.
5. Drug-alcohol interactions: Alcohol can interact with various medications, causing additive sedative effects, impaired judgment, or increased risk of liver damage. For example, combining alcohol with benzodiazepines or opioids can lead to dangerous levels of sedation and respiratory depression.

It is essential for healthcare providers and patients to be aware of potential drug interactions to minimize adverse effects and optimize treatment outcomes.

Biogenic monoamines are a type of neurotransmitter, which are chemical messengers that transmit signals in the brain and other parts of the nervous system. They are called "biogenic" because they are derived from biological substances, and "monoamines" because they contain one amine group (-NH2) and are derived from the aromatic amino acids: tryptophan, tyrosine, and phenylalanine.

Examples of biogenic monoamines include:

1. Serotonin (5-hydroxytryptamine or 5-HT): synthesized from the amino acid tryptophan and plays a crucial role in regulating mood, appetite, sleep, memory, and learning.
2. Dopamine: formed from tyrosine and is involved in reward, motivation, motor control, and reinforcement of behavior.
3. Norepinephrine (noradrenaline): also derived from tyrosine and functions as a neurotransmitter and hormone that modulates attention, arousal, and stress responses.
4. Epinephrine (adrenaline): synthesized from norepinephrine and serves as a crucial hormone and neurotransmitter in the body's fight-or-flight response to stress or danger.
5. Histamine: produced from the amino acid histidine, it acts as a neurotransmitter and mediates allergic reactions, immune responses, and regulates wakefulness and appetite.

Imbalances in biogenic monoamines have been linked to various neurological and psychiatric disorders, such as depression, anxiety, Parkinson's disease, and schizophrenia. Therefore, medications that target these neurotransmitters, like selective serotonin reuptake inhibitors (SSRIs) for depression or levodopa for Parkinson's disease, are often used in the treatment of these conditions.

Clomipramine is a tricyclic antidepressant drug that is primarily used to treat obsessive-compulsive disorder (OCD). It works by increasing the levels of certain neurotransmitters, such as serotonin and norepinephrine, in the brain. These neurotransmitters are involved in regulating mood and behavior.

Clomipramine is also used off-label to treat other conditions, including panic disorder, depression, chronic pain, and sleep disorders. It is available as a tablet or capsule and is typically taken one to three times a day. Common side effects of clomipramine include dry mouth, constipation, blurred vision, dizziness, and drowsiness.

As with all medications, clomipramine should be used under the close supervision of a healthcare provider, who can monitor its effectiveness and potential side effects. It is important to follow the dosage instructions carefully and to report any unusual symptoms or concerns to the healthcare provider promptly.

Serotonin antagonists are a class of drugs that block the action of serotonin, a neurotransmitter, at specific receptor sites in the brain and elsewhere in the body. They work by binding to the serotonin receptors without activating them, thereby preventing the natural serotonin from binding and transmitting signals.

Serotonin antagonists are used in the treatment of various conditions such as psychiatric disorders, migraines, and nausea and vomiting associated with cancer chemotherapy. They can have varying degrees of affinity for different types of serotonin receptors (e.g., 5-HT2A, 5-HT3, etc.), which contributes to their specific therapeutic effects and side effect profiles.

Examples of serotonin antagonists include ondansetron (used to treat nausea and vomiting), risperidone and olanzapine (used to treat psychiatric disorders), and methysergide (used to prevent migraines). It's important to note that these medications should be used under the supervision of a healthcare provider, as they can have potential risks and interactions with other drugs.

Tetrabenazine is a prescription medication used to treat conditions associated with abnormal involuntary movements, such as chorea in Huntington's disease. It works by depleting the neurotransmitter dopamine in the brain, which helps to reduce the severity and frequency of these movements.

Here is the medical definition:

Tetrabenazine is a selective monoamine-depleting agent, with preferential uptake by dopamine neurons. It is used in the treatment of chorea associated with Huntington's disease. Tetrabenazine inhibits vesicular monoamine transporter 2 (VMAT2), leading to depletion of presynaptic dopamine and subsequent reduction in post-synaptic dopamine receptor activation. This mechanism of action is thought to underlie its therapeutic effect in reducing chorea severity and frequency.

(Definitions provided by Stedman's Medical Dictionary and American Society of Health-System Pharmacists)

The mesencephalon, also known as the midbrain, is the middle portion of the brainstem that connects the hindbrain (rhombencephalon) and the forebrain (prosencephalon). It plays a crucial role in several important functions including motor control, vision, hearing, and the regulation of consciousness and sleep-wake cycles. The mesencephalon contains several important structures such as the cerebral aqueduct, tectum, tegmentum, cerebral peduncles, and several cranial nerve nuclei (III and IV).

Pargyline is an antihypertensive drug and a irreversible monoamine oxidase inhibitor (MAOI) of type B. It works by blocking the breakdown of certain chemicals in the brain, such as neurotransmitters, which can help improve mood and behavior in people with depression.

Pargyline is not commonly used as a first-line treatment for depression due to its potential for serious side effects, including interactions with certain foods and medications that can lead to dangerously high blood pressure. It is also associated with a risk of serotonin syndrome when taken with selective serotonin reuptake inhibitors (SSRIs) or other drugs that increase serotonin levels in the brain.

Pargyline is available only through a prescription and should be used under the close supervision of a healthcare provider.

Stereotyped behavior, in the context of medicine and psychology, refers to repetitive, rigid, and invariant patterns of behavior or movements that are purposeless and often non-functional. These behaviors are not goal-directed or spontaneous and typically do not change in response to environmental changes or social interactions.

Stereotypies can include a wide range of motor behaviors such as hand flapping, rocking, head banging, body spinning, self-biting, or complex sequences of movements. They are often seen in individuals with developmental disabilities, intellectual disabilities, autism spectrum disorder, and some mental health conditions.

Stereotyped behaviors can also be a result of substance abuse, neurological disorders, or brain injuries. In some cases, these behaviors may serve as a self-soothing mechanism or a way to cope with stress, anxiety, or boredom. However, they can also interfere with daily functioning and social interactions, and in severe cases, may cause physical harm to the individual.

The brain is the central organ of the nervous system, responsible for receiving and processing sensory information, regulating vital functions, and controlling behavior, movement, and cognition. It is divided into several distinct regions, each with specific functions:

1. Cerebrum: The largest part of the brain, responsible for higher cognitive functions such as thinking, learning, memory, language, and perception. It is divided into two hemispheres, each controlling the opposite side of the body.
2. Cerebellum: Located at the back of the brain, it is responsible for coordinating muscle movements, maintaining balance, and fine-tuning motor skills.
3. Brainstem: Connects the cerebrum and cerebellum to the spinal cord, controlling vital functions such as breathing, heart rate, and blood pressure. It also serves as a relay center for sensory information and motor commands between the brain and the rest of the body.
4. Diencephalon: A region that includes the thalamus (a major sensory relay station) and hypothalamus (regulates hormones, temperature, hunger, thirst, and sleep).
5. Limbic system: A group of structures involved in emotional processing, memory formation, and motivation, including the hippocampus, amygdala, and cingulate gyrus.

The brain is composed of billions of interconnected neurons that communicate through electrical and chemical signals. It is protected by the skull and surrounded by three layers of membranes called meninges, as well as cerebrospinal fluid that provides cushioning and nutrients.

The Substantia Nigra is a region in the midbrain that plays a crucial role in movement control and reward processing. It is composed of two parts: the pars compacta and the pars reticulata. The pars compacta contains dopamine-producing neurons, whose loss or degeneration is associated with Parkinson's disease, leading to motor symptoms such as tremors, rigidity, and bradykinesia.

In summary, Substantia Nigra is a brain structure that contains dopamine-producing cells and is involved in movement control and reward processing. Its dysfunction or degeneration can lead to neurological disorders like Parkinson's disease.

"Cocaine-Related Disorders" is a term used in the medical and psychiatric fields to refer to a group of conditions related to the use of cocaine, a powerful stimulant drug. These disorders are classified and diagnosed based on the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), published by the American Psychiatric Association.

The two main categories of Cocaine-Related Disorders are:

1. Cocaine Use Disorder: This disorder is characterized by a problematic pattern of cocaine use leading to clinically significant impairment or distress, as manifested by at least two symptoms within a 12-month period. These symptoms may include using larger amounts of cocaine over a longer period than intended, persistent desire or unsuccessful efforts to cut down or control cocaine use, spending a great deal of time obtaining, using, or recovering from the effects of cocaine, and continued use despite physical or psychological problems caused or exacerbated by cocaine.
2. Cocaine-Induced Disorders: These disorders are directly caused by the acute effects of cocaine intoxication or withdrawal. They include:
* Cocaine Intoxication: Presents with a reversible syndrome due to recent use of cocaine, characterized by euphoria, increased energy, and psychomotor agitation. It may also cause elevated heart rate, blood pressure, and body temperature, as well as pupillary dilation.
* Cocaine Withdrawal: Occurs when an individual who has been using cocaine heavily for a prolonged period abruptly stops or significantly reduces their use. Symptoms include depressed mood, fatigue, increased appetite, vivid and unpleasant dreams, and insomnia.

Cocaine-Related Disorders can have severe negative consequences on an individual's physical health, mental wellbeing, and social functioning. They often require professional treatment to manage and overcome.

Carrier proteins, also known as transport proteins, are a type of protein that facilitates the movement of molecules across cell membranes. They are responsible for the selective and active transport of ions, sugars, amino acids, and other molecules from one side of the membrane to the other, against their concentration gradient. This process requires energy, usually in the form of ATP (adenosine triphosphate).

Carrier proteins have a specific binding site for the molecule they transport, and undergo conformational changes upon binding, which allows them to move the molecule across the membrane. Once the molecule has been transported, the carrier protein returns to its original conformation, ready to bind and transport another molecule.

Carrier proteins play a crucial role in maintaining the balance of ions and other molecules inside and outside of cells, and are essential for many physiological processes, including nerve impulse transmission, muscle contraction, and nutrient uptake.

Neurons, also known as nerve cells or neurocytes, are specialized cells that constitute the basic unit of the nervous system. They are responsible for receiving, processing, and transmitting information and signals within the body. Neurons have three main parts: the dendrites, the cell body (soma), and the axon. The dendrites receive signals from other neurons or sensory receptors, while the axon transmits these signals to other neurons, muscles, or glands. The junction between two neurons is called a synapse, where neurotransmitters are released to transmit the signal across the gap (synaptic cleft) to the next neuron. Neurons vary in size, shape, and structure depending on their function and location within the nervous system.

Methysergide, commonly known as methylergometrine or metergoline, is not typically considered a medication in the medical field. It is actually a derivative of ergot alkaloids, which are fungal metabolites that have been used in medicine for their vasoconstrictive and oxytocic properties.

Methysergide has been used in the past as a migraine prophylaxis medication due to its ability to block serotonin receptors in the brain. However, its use is now limited due to its potential to cause serious side effects such as fibrotic reactions in various organs, including the heart, lungs, and kidneys.

Therefore, methysergide/metergoline is not commonly used in modern medical practice, and its use is typically reserved for highly specific cases under close medical supervision.

Fenfluramine is a drug that was previously used for the short-term treatment of obesity. It works by suppressing appetite and increasing the feeling of fullness. Fenfluramine is an amphetamine derivative and stimulates the release of serotonin, a neurotransmitter in the brain that helps regulate mood, appetite, and sleep.

Fenfluramine was commonly prescribed in combination with phentermine, another appetite suppressant, under the brand name Fen-Phen. However, in 1997, the U.S. Food and Drug Administration (FDA) issued a public health warning about the potential risk of serious heart valve damage associated with the use of fenfluramine and withdrew its approval for the drug's use. Since then, fenfluramine has not been approved for medical use in many countries, including the United States.

Protriptyline is a tricyclic antidepressant (TCA) medication. It is primarily used to treat symptoms of depression, but it can also be used for other conditions such as anxiety disorders or to help manage chronic pain. Protriptyline works by increasing the levels of certain neurotransmitters in the brain, such as norepinephrine and serotonin, which can help to improve mood and reduce symptoms of depression.

Protriptyline has a sedating effect, so it may also be used to treat insomnia or agitation associated with depression. It is available in immediate-release tablet form and is typically taken two to four times per day. As with all medications, protriptyline can have side effects, including dry mouth, blurred vision, constipation, and dizziness. It may also cause cardiac arrhythmias and should be used with caution in patients with a history of heart disease.

It's important to note that the use of Protriptyline and other tricyclic antidepressants has declined over the years due to the development of newer classes of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), which have fewer side effects and are safer in overdose. However, protriptyline may still be prescribed in certain cases where other treatments have not been effective.

Reserpine is an alkaloid derived from the Rauwolfia serpentina plant, which has been used in traditional medicine for its sedative and hypotensive effects. In modern medicine, reserpine is primarily used to treat hypertension (high blood pressure) due to its ability to lower both systolic and diastolic blood pressure.

Reserpine works by depleting catecholamines, including norepinephrine, epinephrine, and dopamine, from nerve terminals in the sympathetic nervous system. This leads to a decrease in peripheral vascular resistance and heart rate, ultimately resulting in reduced blood pressure.

Reserpine is available in various forms, such as tablets or capsules, and is typically administered orally. Common side effects include nasal congestion, dizziness, sedation, and gastrointestinal disturbances like diarrhea and nausea. Long-term use of reserpine may also lead to depression in some individuals. Due to its potential for causing depression, other antihypertensive medications are often preferred over reserpine when possible.

Quipazine is not generally considered a medical term, but it is a chemical compound that has been studied in the field of medicine and neuroscience. Quipazine is a type of drug known as a serotonin receptor agonist, which means it binds to and activates serotonin receptors in the brain.

Serotonin is a neurotransmitter, a chemical that transmits signals in the brain and nervous system, that plays a role in regulating mood, appetite, sleep, and other functions. Quipazine has been studied for its potential therapeutic uses in various conditions, including depression, anxiety, schizophrenia, and substance abuse disorders. However, it is not currently approved for use as a medication in any country.

It's important to note that while quipazine may have potential therapeutic benefits, it also has significant side effects, including seizures, changes in heart rate and blood pressure, and neuroleptic malignant syndrome, a potentially life-threatening condition characterized by muscle rigidity, fever, and autonomic dysfunction. As such, its use is generally limited to research settings.

1-Methyl-4-phenylpyridinium (MPP+) is a neurotoxic compound that is widely used in scientific research to study Parkinson's disease and other neurological disorders. MPP+ is an ionic form of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is a lipophilic compound that can cross the blood-brain barrier and be converted to MPP+ by monoamine oxidase B (MAO-B) in glial cells.

MPP+ is taken up by dopaminergic neurons through the dopamine transporter (DAT), where it inhibits complex I of the electron transport chain, leading to mitochondrial dysfunction and energy depletion. This results in the death of dopaminergic neurons, which are the primary cells affected in Parkinson's disease.

MPP+ has been used as a model compound to study the mechanisms of neurodegeneration in Parkinson's disease and other neurological disorders, and it has also been used in the development of potential therapeutic strategies for these conditions.

Amphetamines are a type of central nervous system stimulant drug that increases alertness, wakefulness, and energy levels. They work by increasing the activity of certain neurotransmitters (chemical messengers) in the brain, such as dopamine and norepinephrine. Amphetamines can be prescribed for medical conditions such as attention deficit hyperactivity disorder (ADHD) and narcolepsy, but they are also commonly abused for their ability to produce euphoria, increase confidence, and improve performance in tasks that require sustained attention.

Some common examples of amphetamines include:

* Adderall: a combination of amphetamine and dextroamphetamine, used to treat ADHD and narcolepsy
* Dexedrine: a brand name for dextroamphetamine, used to treat ADHD and narcolepsy
* Vyvanse: a long-acting formulation of lisdexamfetamine, a prodrug that is converted to dextroamphetamine in the body, used to treat ADHD

Amphetamines can be taken orally, snorted, smoked, or injected. Long-term use or abuse of amphetamines can lead to a number of negative health consequences, including addiction, cardiovascular problems, malnutrition, mental health disorders, and memory loss.

"Competitive binding" is a term used in pharmacology and biochemistry to describe the behavior of two or more molecules (ligands) competing for the same binding site on a target protein or receptor. In this context, "binding" refers to the physical interaction between a ligand and its target.

When a ligand binds to a receptor, it can alter the receptor's function, either activating or inhibiting it. If multiple ligands compete for the same binding site, they will compete to bind to the receptor. The ability of each ligand to bind to the receptor is influenced by its affinity for the receptor, which is a measure of how strongly and specifically the ligand binds to the receptor.

In competitive binding, if one ligand is present in high concentrations, it can prevent other ligands with lower affinity from binding to the receptor. This is because the higher-affinity ligand will have a greater probability of occupying the binding site and blocking access to the other ligands. The competition between ligands can be described mathematically using equations such as the Langmuir isotherm, which describes the relationship between the concentration of ligand and the fraction of receptors that are occupied by the ligand.

Competitive binding is an important concept in drug development, as it can be used to predict how different drugs will interact with their targets and how they may affect each other's activity. By understanding the competitive binding properties of a drug, researchers can optimize its dosage and delivery to maximize its therapeutic effect while minimizing unwanted side effects.

Quinpirole is not a medical condition or disease, but rather a synthetic compound used in research and medicine. It's a selective agonist for the D2 and D3 dopamine receptors, which means it binds to and activates these receptors, mimicking the effects of dopamine, a neurotransmitter involved in various physiological processes such as movement, motivation, reward, and cognition.

Quinpirole is used primarily in preclinical research to study the role of dopamine receptors in different neurological conditions, including Parkinson's disease, schizophrenia, drug addiction, and others. It helps researchers understand how dopamine systems work and contributes to the development of new therapeutic strategies for these disorders.

It is important to note that quinpirole is not used as a medication in humans or animals but rather as a research tool in laboratory settings.

Self-administration, in the context of medicine and healthcare, refers to the act of an individual administering medication or treatment to themselves. This can include various forms of delivery such as oral medications, injections, or topical treatments. It is important that individuals who self-administer are properly trained and understand the correct dosage, timing, and technique to ensure safety and effectiveness. Self-administration promotes independence, allows for timely treatment, and can improve overall health outcomes.

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) medication that is primarily used to treat major depressive disorders, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and post-traumatic stress disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance, leading to an improvement in mood and other symptoms associated with these conditions.

Paroxetine is available under various brand names, such as Paxil and Seroxat, and it comes in different forms, including tablets, capsules, and liquid solutions. The medication is typically taken once daily, although the dosage may vary depending on the individual's needs and the specific condition being treated.

As with any medication, paroxetine can have side effects, such as nausea, dizziness, dry mouth, and sleep disturbances. In some cases, it may also cause more serious side effects, including increased risk of suicidal thoughts or behaviors in children, adolescents, and young adults, as well as an increased risk of bleeding and hyponatremia (low sodium levels).

It is important to consult with a healthcare provider before starting paroxetine or any other medication, and to follow their instructions carefully regarding dosage, timing, and potential interactions with other drugs or medical conditions.

Tritium is not a medical term, but it is a term used in the field of nuclear physics and chemistry. Tritium (symbol: T or 3H) is a radioactive isotope of hydrogen with two neutrons and one proton in its nucleus. It is also known as heavy hydrogen or superheavy hydrogen.

Tritium has a half-life of about 12.3 years, which means that it decays by emitting a low-energy beta particle (an electron) to become helium-3. Due to its radioactive nature and relatively short half-life, tritium is used in various applications, including nuclear weapons, fusion reactors, luminous paints, and medical research.

In the context of medicine, tritium may be used as a radioactive tracer in some scientific studies or medical research, but it is not a term commonly used to describe a medical condition or treatment.

Fluvoxamine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance. Fluvoxamine is primarily used to treat obsessive-compulsive disorder (OCD) and may also be prescribed for other conditions such as depression, panic disorder, or social anxiety disorder.

The medical definition of Fluvoxamine can be stated as:

Fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI), is a psychotropic medication used primarily in the treatment of obsessive-compulsive disorder (OCD). It functions by increasing the availability of serotonin in the synaptic cleft, which subsequently modulates neurotransmission and helps restore emotional balance. Fluvoxamine may also be employed off-label for managing other conditions, such as depression, panic disorder, or social anxiety disorder, subject to clinical judgment and patient needs.

Benzazepines are a class of heterocyclic compounds that contain a benzene fused to a diazepine ring. In the context of pharmaceuticals, benzazepines refer to a group of drugs with various therapeutic uses, such as antipsychotics and antidepressants. Some examples of benzazepine-derived drugs include clozapine, olanzapine, and loxoprofen. These drugs have complex mechanisms of action, often involving multiple receptor systems in the brain.

Dicarboxylic acids are organic compounds containing two carboxyl groups (-COOH) in their molecular structure. The general formula for dicarboxylic acids is HOOC-R-COOH, where R represents a hydrocarbon chain or a functional group.

The presence of two carboxyl groups makes dicarboxylic acids stronger acids than monocarboxylic acids (compounds containing only one -COOH group). This is because the second carboxyl group contributes to the acidity of the molecule, allowing it to donate two protons in solution.

Examples of dicarboxylic acids include oxalic acid (HOOC-COOH), malonic acid (CH2(COOH)2), succinic acid (HOOC-CH2-CH2-COOH), glutaric acid (HOOC-(CH2)3-COOH), and adipic acid (HOOC-(CH2)4-COOH). These acids have various industrial applications, such as in the production of polymers, dyes, and pharmaceuticals.

3,4-Dihydroxyphenylacetic Acid (3,4-DOPAC) is a major metabolite of dopamine, which is a neurotransmitter in the brain. Dopamine is metabolized by the enzyme monoamine oxidase to form dihydroxyphenylacetaldehyde, which is then further metabolized to 3,4-DOPAC by the enzyme aldehyde dehydrogenase.

3,4-DOPAC is found in the urine and can be used as a marker for dopamine turnover in the brain. Changes in the levels of 3,4-DOPAC have been associated with various neurological disorders such as Parkinson's disease and schizophrenia. Additionally, 3,4-DOPAC has been shown to have antioxidant properties and may play a role in protecting against oxidative stress in the brain.

Brain chemistry refers to the chemical processes that occur within the brain, particularly those involving neurotransmitters, neuromodulators, and neuropeptides. These chemicals are responsible for transmitting signals between neurons (nerve cells) in the brain, allowing for various cognitive, emotional, and physical functions.

Neurotransmitters are chemical messengers that transmit signals across the synapse (the tiny gap between two neurons). Examples of neurotransmitters include dopamine, serotonin, norepinephrine, GABA (gamma-aminobutyric acid), and glutamate. Each neurotransmitter has a specific role in brain function, such as regulating mood, motivation, attention, memory, and movement.

Neuromodulators are chemicals that modify the effects of neurotransmitters on neurons. They can enhance or inhibit the transmission of signals between neurons, thereby modulating brain activity. Examples of neuromodulators include acetylcholine, histamine, and substance P.

Neuropeptides are small protein-like molecules that act as neurotransmitters or neuromodulators. They play a role in various physiological functions, such as pain perception, stress response, and reward processing. Examples of neuropeptides include endorphins, enkephalins, and oxytocin.

Abnormalities in brain chemistry can lead to various neurological and psychiatric conditions, such as depression, anxiety disorders, schizophrenia, Parkinson's disease, and Alzheimer's disease. Understanding brain chemistry is crucial for developing effective treatments for these conditions.

In the context of medicine and pharmacology, "kinetics" refers to the study of how a drug moves throughout the body, including its absorption, distribution, metabolism, and excretion (often abbreviated as ADME). This field is called "pharmacokinetics."

1. Absorption: This is the process of a drug moving from its site of administration into the bloodstream. Factors such as the route of administration (e.g., oral, intravenous, etc.), formulation, and individual physiological differences can affect absorption.

2. Distribution: Once a drug is in the bloodstream, it gets distributed throughout the body to various tissues and organs. This process is influenced by factors like blood flow, protein binding, and lipid solubility of the drug.

3. Metabolism: Drugs are often chemically modified in the body, typically in the liver, through processes known as metabolism. These changes can lead to the formation of active or inactive metabolites, which may then be further distributed, excreted, or undergo additional metabolic transformations.

4. Excretion: This is the process by which drugs and their metabolites are eliminated from the body, primarily through the kidneys (urine) and the liver (bile).

Understanding the kinetics of a drug is crucial for determining its optimal dosing regimen, potential interactions with other medications or foods, and any necessary adjustments for special populations like pediatric or geriatric patients, or those with impaired renal or hepatic function.

Imipramine is a tricyclic antidepressant (TCA) medication that is primarily used to treat depression. It works by increasing the levels of certain neurotransmitters, such as serotonin and norepinephrine, in the brain. Imipramine has been found to be effective in treating various types of depression, including major depressive disorder, dysthymia, and depression that is resistant to other treatments.

In addition to its antidepressant effects, imipramine is also used off-label for the treatment of several other conditions, such as anxiety disorders, attention deficit hyperactivity disorder (ADHD), enuresis (bedwetting), and chronic pain.

Imipramine was first synthesized in the 1950s and has been widely used since then. It is available in various forms, including immediate-release tablets, extended-release capsules, and liquid solutions. As with all medications, imipramine can have side effects, which may include dry mouth, blurred vision, constipation, dizziness, and sedation. In rare cases, it can cause more serious side effects, such as cardiac arrhythmias or seizures.

It is important to use imipramine under the close supervision of a healthcare provider, as dosages may need to be adjusted based on individual patient needs and responses to treatment. Additionally, imipramine should not be stopped abruptly, as doing so can lead to withdrawal symptoms or a recurrence of depression.

Central nervous system (CNS) stimulants are a class of drugs that increase alertness, attention, energy, and/or mood by directly acting on the brain. They can be prescribed to treat medical conditions such as narcolepsy, attention deficit hyperactivity disorder (ADHD), and depression that has not responded to other treatments.

Examples of CNS stimulants include amphetamine (Adderall), methylphenidate (Ritalin, Concerta), and modafinil (Provigil). These medications work by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain.

In addition to their therapeutic uses, CNS stimulants are also sometimes misused for non-medical reasons, such as to enhance cognitive performance or to get high. However, it's important to note that misusing these drugs can lead to serious health consequences, including addiction, cardiovascular problems, and mental health issues.

Tyramine is not a medical condition but a naturally occurring compound called a biogenic amine, which is formed from the amino acid tyrosine during the fermentation or decay of certain foods. Medically, tyramine is significant because it can interact with certain medications, particularly monoamine oxidase inhibitors (MAOIs), used to treat depression and other conditions.

The interaction between tyramine and MAOIs can lead to a hypertensive crisis, a rapid and severe increase in blood pressure, which can be life-threatening if not treated promptly. Therefore, individuals taking MAOIs are often advised to follow a low-tyramine diet, avoiding foods high in tyramine, such as aged cheeses, cured meats, fermented foods, and some types of beer and wine.

Raclopride is not a medical condition but a drug that belongs to the class of dopamine receptor antagonists. It's primarily used in research and diagnostic settings as a radioligand in positron emission tomography (PET) scans to visualize and measure the distribution and availability of dopamine D2 and D3 receptors in the brain.

In simpler terms, Raclopride is a compound that can be labeled with a radioactive isotope and then introduced into the body to track the interaction between the radioligand and specific receptors (in this case, dopamine D2 and D3 receptors) in the brain. This information can help researchers and clinicians better understand neurochemical processes and disorders related to dopamine dysfunction, such as Parkinson's disease, schizophrenia, and drug addiction.

It is important to note that Raclopride is not used as a therapeutic agent in clinical practice due to its short half-life and the potential for side effects associated with dopamine receptor blockade.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Monoamine oxidase inhibitors (MAOIs) are a class of drugs that work by blocking the action of monoamine oxidase, an enzyme found in the brain and other organs of the body. This enzyme is responsible for breaking down certain neurotransmitters, such as serotonin, dopamine, and norepinephrine, which are chemicals that transmit signals in the brain.

By inhibiting the action of monoamine oxidase, MAOIs increase the levels of these neurotransmitters in the brain, which can help to alleviate symptoms of depression and other mood disorders. However, MAOIs also affect other chemicals in the body, including tyramine, a substance found in some foods and beverages, as well as certain medications. As a result, MAOIs can have serious side effects and interactions with other substances, making them a less commonly prescribed class of antidepressants than other types of drugs.

MAOIs are typically used as a last resort when other treatments for depression have failed, due to their potential for dangerous interactions and side effects. They require careful monitoring and dosage adjustment by a healthcare provider, and patients must follow strict dietary restrictions while taking them.

Serotonin plasma membrane transport proteins, also known as serotonin transporters (SERTs), are membrane-spanning proteins that play a crucial role in the regulation of serotonergic neurotransmission. They are responsible for the reuptake of serotonin (5-hydroxytryptamine or 5-HT) from the synaptic cleft back into the presynaptic neuron, thereby terminating the signal transmission and allowing for its recycling or degradation.

Structurally, SERTs belong to the family of sodium- and chloride-dependent neurotransmitter transporters and contain 12 transmembrane domains with intracellular N- and C-termini. The binding site for serotonin is located within the transmembrane domain, while the substrate-binding site is formed by residues from both the transmembrane and extracellular loops.

Serotonin transporters are important targets for various psychotropic medications, including selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). These drugs act by blocking the SERT, increasing synaptic concentrations of serotonin, and enhancing serotonergic neurotransmission. Dysregulation of serotonin transporters has been implicated in several neurological and psychiatric disorders, such as major depressive disorder, anxiety disorders, obsessive-compulsive disorder, and substance abuse.

Citalopram is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance. Citalopram is primarily used to treat major depressive disorder and is also sometimes used to treat anxiety disorders, such as panic disorder or social anxiety disorder.

The medical definition of Citalopram can be described as follows:

Citalopram (brand name Celexa) is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is primarily used to treat major depressive disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance. Citalopram may also be used off-label for the treatment of anxiety disorders, such as panic disorder or social anxiety disorder.

Common side effects of citalopram include nausea, dry mouth, increased sweating, sleepiness, fatigue, and insomnia. More serious side effects can include an increased risk of suicidal thoughts or behavior in children, adolescents, and young adults, as well as an increased risk of bleeding, particularly if taken with other medications that increase the risk of bleeding. Citalopram should be used with caution in patients with a history of heart disease, liver disease, or seizure disorders. It is important to follow the dosage instructions provided by your healthcare provider and to inform them of any other medications you are taking, as well as any medical conditions you have, before starting citalopram.

N-Methyl-3,4-methylenedioxyamphetamine (also known as MDA) is a synthetic psychoactive drug that belongs to the class of amphetamines. It acts as a central nervous system stimulant and hallucinogen. Chemically, it is a derivative of amphetamine with an additional methylenedioxy ring attached to the 3,4 positions on the aromatic ring. MDA is known for its empathogenic effects, meaning that it can produce feelings of empathy, emotional openness, and euphoria in users. It has been used recreationally as a party drug and at raves, but it also has potential therapeutic uses. However, MDA can have serious side effects, including increased heart rate and blood pressure, hyperthermia, dehydration, and in some cases, serotonin syndrome. As with other psychoactive drugs, MDA should only be used under medical supervision and with a clear understanding of its potential risks and benefits.

Serotonin receptors are a type of cell surface receptor that bind to the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). They are widely distributed throughout the body, including the central and peripheral nervous systems, where they play important roles in regulating various physiological processes such as mood, appetite, sleep, memory, learning, and cognition.

There are seven different classes of serotonin receptors (5-HT1 to 5-HT7), each with multiple subtypes, that exhibit distinct pharmacological properties and signaling mechanisms. These receptors are G protein-coupled receptors (GPCRs) or ligand-gated ion channels, which activate intracellular signaling pathways upon serotonin binding.

Serotonin receptors have been implicated in various neurological and psychiatric disorders, including depression, anxiety, schizophrenia, and migraine. Therefore, selective serotonin receptor agonists or antagonists are used as therapeutic agents for the treatment of these conditions.

Dextroamphetamine is a central nervous system stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It works by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain. Dextroamphetamine is available as a prescription medication and is sold under various brand names, including Adderall and Dexedrine. It is important to use this medication only as directed by a healthcare professional, as it can have potentially serious side effects if used improperly.

Pyrrolidines are not a medical term per se, but they are a chemical compound that can be encountered in the field of medicine and pharmacology. Pyrrolidine is an organic compound with the molecular formula (CH2)4NH. It is a cyclic secondary amine, which means it contains a nitrogen atom surrounded by four carbon atoms in a ring structure.

Pyrrolidines can be found in certain natural substances and are also synthesized for use in pharmaceuticals and research. They have been used as building blocks in the synthesis of various drugs, including some muscle relaxants, antipsychotics, and antihistamines. Additionally, pyrrolidine derivatives can be found in certain plants and fungi, where they may contribute to biological activity or toxicity.

It is important to note that while pyrrolidines themselves are not a medical condition or diagnosis, understanding their chemical properties and uses can be relevant to the study and development of medications.

Sulpiride is an antipsychotic drug that belongs to the chemical class of benzamides. It primarily acts as a selective dopamine D2 and D3 receptor antagonist. Sulpiride is used in the treatment of various psychiatric disorders such as schizophrenia, psychosis, anxiety, and depression. In addition, it has been found to be effective in managing gastrointestinal disorders like gastroparesis due to its prokinetic effects on the gastrointestinal tract.

The medical definition of Sulpiride is as follows:

Sulpiride (INN, BAN), also known as Sultopride (USAN) or SP, is a selective dopamine D2 and D3 receptor antagonist used in the treatment of various psychiatric disorders such as schizophrenia, psychosis, anxiety, and depression. It has been found to be effective in managing gastrointestinal disorders like gastroparesis due to its prokinetic effects on the gastrointestinal tract. Sulpiride is available under various brand names worldwide, including Dogmatil, Sulpitac, and Espirid."

Please note that this definition includes information about the drug's therapeutic uses, which are essential aspects of understanding a medication in its entirety.

Adenosine is a purine nucleoside that is composed of a sugar (ribose) and the base adenine. It plays several important roles in the body, including serving as a precursor for the synthesis of other molecules such as ATP, NAD+, and RNA.

In the medical context, adenosine is perhaps best known for its use as a pharmaceutical agent to treat certain cardiac arrhythmias. When administered intravenously, it can help restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT) by slowing conduction through the atrioventricular node and interrupting the reentry circuit responsible for the arrhythmia.

Adenosine can also be used as a diagnostic tool to help differentiate between narrow-complex tachycardias of supraventricular origin and those that originate from below the ventricles (such as ventricular tachycardia). This is because adenosine will typically terminate PSVT but not affect the rhythm of VT.

It's worth noting that adenosine has a very short half-life, lasting only a few seconds in the bloodstream. This means that its effects are rapidly reversible and generally well-tolerated, although some patients may experience transient symptoms such as flushing, chest pain, or shortness of breath.

Salicylamides are organic compounds that consist of a salicylic acid molecule (a type of phenolic acid) linked to an amide group. They are derivatives of salicylic acid and are known for their analgesic, anti-inflammatory, and antipyretic properties. Salicylamides have been used in various pharmaceutical and therapeutic applications, including the treatment of pain, fever, and inflammation. However, they have largely been replaced by other compounds such as acetylsalicylic acid (aspirin) due to their lower potency and potential side effects.

Haloperidol is an antipsychotic medication, which is primarily used to treat schizophrenia and symptoms of psychosis, such as delusions, hallucinations, paranoia, or disordered thought. It may also be used to manage Tourette's disorder, tics, agitation, aggression, and hyperactivity in children with developmental disorders.

Haloperidol works by blocking the action of dopamine, a neurotransmitter in the brain, which helps to regulate mood and behavior. It is available in various forms, including tablets, liquid, and injectable solutions. The medication can cause side effects such as drowsiness, restlessness, muscle stiffness, and uncontrolled movements. In rare cases, it may also lead to more serious neurological side effects.

As with any medication, haloperidol should be taken under the supervision of a healthcare provider, who will consider the individual's medical history, current medications, and other factors before prescribing it.

Apomorphine is a non-selective dopamine receptor agonist, which means that it activates dopamine receptors in the brain. It has a high affinity for D1 and D2 dopamine receptors and is used medically to treat Parkinson's disease, particularly in cases of severe or intractable motor fluctuations.

Apomorphine can be administered subcutaneously (under the skin) as a solution or as a sublingual (under the tongue) film. It works by stimulating dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease such as stiffness, tremors, and difficulty with movement.

In addition to its use in Parkinson's disease, apomorphine has also been investigated for its potential therapeutic benefits in other neurological disorders, including alcohol use disorder and drug addiction. However, more research is needed to establish its safety and efficacy in these conditions.

Dipyridamole is a medication that belongs to a class of drugs called antiplatelet agents. It works by preventing platelets in your blood from sticking together to form clots. Dipyridamole is often used in combination with aspirin to prevent stroke and other complications in people who have had a heart valve replacement or a type of irregular heartbeat called atrial fibrillation.

Dipyridamole can also be used as a stress agent in myocardial perfusion imaging studies, which are tests used to evaluate blood flow to the heart. When used for this purpose, dipyridamole is given intravenously and works by dilating the blood vessels in the heart, allowing more blood to flow through them and making it easier to detect areas of reduced blood flow.

The most common side effects of dipyridamole include headache, dizziness, and gastrointestinal symptoms such as diarrhea, nausea, and vomiting. In rare cases, dipyridamole can cause more serious side effects, such as allergic reactions, abnormal heart rhythms, or low blood pressure. It is important to take dipyridamole exactly as directed by your healthcare provider and to report any unusual symptoms or side effects promptly.

Gamma-Aminobutyric Acid (GABA) is a major inhibitory neurotransmitter in the mammalian central nervous system. It plays a crucial role in regulating neuronal excitability and preventing excessive neuronal firing, which helps to maintain neural homeostasis and reduce the risk of seizures. GABA functions by binding to specific receptors (GABA-A, GABA-B, and GABA-C) on the postsynaptic membrane, leading to hyperpolarization of the neuronal membrane and reduced neurotransmitter release from presynaptic terminals.

In addition to its role in the central nervous system, GABA has also been identified as a neurotransmitter in the peripheral nervous system, where it is involved in regulating various physiological processes such as muscle relaxation, hormone secretion, and immune function.

GABA can be synthesized in neurons from glutamate, an excitatory neurotransmitter, through the action of the enzyme glutamic acid decarboxylase (GAD). Once synthesized, GABA is stored in synaptic vesicles and released into the synapse upon neuronal activation. After release, GABA can be taken up by surrounding glial cells or degraded by the enzyme GABA transaminase (GABA-T) into succinic semialdehyde, which is further metabolized to form succinate and enter the Krebs cycle for energy production.

Dysregulation of GABAergic neurotransmission has been implicated in various neurological and psychiatric disorders, including epilepsy, anxiety, depression, and sleep disturbances. Therefore, modulating GABAergic signaling through pharmacological interventions or other therapeutic approaches may offer potential benefits for the treatment of these conditions.

Catecholamines are a group of hormones and neurotransmitters that are derived from the amino acid tyrosine. The most well-known catecholamines are dopamine, norepinephrine (also known as noradrenaline), and epinephrine (also known as adrenaline). These hormones are produced by the adrenal glands and are released into the bloodstream in response to stress. They play important roles in the "fight or flight" response, increasing heart rate, blood pressure, and alertness. In addition to their role as hormones, catecholamines also function as neurotransmitters, transmitting signals in the nervous system. Disorders of catecholamine regulation can lead to a variety of medical conditions, including hypertension, mood disorders, and neurological disorders.

Synaptic vesicles are tiny membrane-enclosed sacs within the presynaptic terminal of a neuron, containing neurotransmitters. They play a crucial role in the process of neurotransmission, which is the transmission of signals between nerve cells. When an action potential reaches the presynaptic terminal, it triggers the fusion of synaptic vesicles with the plasma membrane, releasing neurotransmitters into the synaptic cleft. These neurotransmitters can then bind to receptors on the postsynaptic neuron and trigger a response. After release, synaptic vesicles are recycled through endocytosis, allowing them to be refilled with neurotransmitters and used again in subsequent rounds of neurotransmission.

Glutamic acid is an alpha-amino acid, which is one of the 20 standard amino acids in the genetic code. The systematic name for this amino acid is (2S)-2-Aminopentanedioic acid. Its chemical formula is HO2CCH(NH2)CH2CH2CO2H.

Glutamic acid is a crucial excitatory neurotransmitter in the human brain, and it plays an essential role in learning and memory. It's also involved in the metabolism of sugars and amino acids, the synthesis of proteins, and the removal of waste nitrogen from the body.

Glutamic acid can be found in various foods such as meat, fish, beans, eggs, dairy products, and vegetables. In the human body, glutamic acid can be converted into gamma-aminobutyric acid (GABA), another important neurotransmitter that has a calming effect on the nervous system.

Levodopa, also known as L-dopa, is a medication used primarily in the treatment of Parkinson's disease. It is a direct precursor to the neurotransmitter dopamine and works by being converted into dopamine in the brain, helping to restore the balance between dopamine and other neurotransmitters. This helps alleviate symptoms such as stiffness, tremors, spasms, and poor muscle control. Levodopa is often combined with carbidopa (a peripheral decarboxylase inhibitor) to prevent the conversion of levodopa to dopamine outside of the brain, reducing side effects like nausea and vomiting.

Endocannabinoids are naturally occurring compounds in the body that bind to cannabinoid receptors, which are found in various tissues and organs throughout the body. These compounds play a role in regulating many physiological processes, including appetite, mood, pain sensation, and memory. They are similar in structure to the active components of cannabis (marijuana), called phytocannabinoids, such as THC (tetrahydrocannabinol) and CBD (cannabidiol). However, endocannabinoids are produced by the body itself, whereas phytocannabinoids come from the cannabis plant. The two most well-known endocannabinoids are anandamide and 2-arachidonoylglycerol (2-AG).

"Synthesis of 3-arylecgonine analogues as inhibitors of cocaine binding and dopamine uptake". Journal of Medicinal Chemistry. 33 ... Troparil is a few times more potent than cocaine as a dopamine reuptake inhibitor, but is less potent as a serotonin reuptake ... Troparil is a phenyltropane-based dopamine reuptake inhibitor (DRI) that is derived from methylecgonidine. ... dopamine uptake inhibition, and locomotor stimulant activity of 2-substituted 3 beta-phenyltropane derivatives". Journal of ...
Li SM, Campbell BL, Katz JL (June 2006). "Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats ... "Synthesis of 3-arylecgonine analogues as inhibitors of cocaine binding and dopamine uptake". Journal of Medicinal Chemistry. 33 ... CFT is a phenyltropane based dopamine reuptake inhibitor and is structurally derived from cocaine. It is around 3-10x more ... Dopamine reuptake inhibitors, Stimulants, Sympathomimetic amines, Medical imaging, Neuroimaging, Fluoroarenes, Methyl esters). ...
"Synthesis of 3-arylecgonine analogues as inhibitors of cocaine binding and dopamine uptake". Journal of Medicinal Chemistry. 33 ...
There are very distinct differences in the mode of action between dopamine releasers/substrates & dopamine re-uptake inhibitors ... Kintscher, U (2012). "Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin". Reuptake Inhibitors of Dopamine, ... A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter ... a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse". Biol. Psychiatry. 72 (5): 405-13. doi: ...
3 beta-Substituted ecgonine methyl esters as inhibitors for cocaine binding and dopamine uptake". Journal of Medicinal ... CPCA bind to the dopamine transporter and inhibit dopamine uptake, stimulate motor activity in rodents and completely ... 2. Potent dopamine and serotonin reuptake inhibitors". Journal of Medicinal Chemistry. 43 (6): 1215-1222. doi:10.1021/jm9905561 ... February 2000). "Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4- ...
... a New Selective Dopamine Uptake Inhibitor". European Journal of Pharmacology. 183 (4): 1416-1417. doi:10.1016/0014-2999(90) ... Unlike other similar drugs, GYKI 52895 is a selective dopamine reuptake inhibitor (DARI), which appears to have an atypical ... Dopamine reuptake inhibitors, Anilines, Benzodiazepines, Benzodioxoles, Abandoned drugs). ... Vaarmann A, Gandhi S, Gourine AV, Abramov AY (2010). "Novel pathway for an old neurotransmitter: dopamine-induced neuronal ...
"Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats". European ... Andersen PH (August 1989). "The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action". European Journal ... 1982). "Diclofensine (Ro 8-4650)--a potent inhibitor of monoamine uptake: biochemical and behavioural effects in comparison ... "Pure uptake blockers of dopamine can reduce prolactin secretion: studies with diclofensine". Life Sciences. 42 (21): 2161-9. ...
... selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine". The Journal of Pharmacology and ... which acts as a potent and selective dopamine reuptake inhibitor. Difluoropine is unique among the tropane-derived dopamine ... November 2006). "Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with ... Dopamine reuptake inhibitors, Stimulants, Diphenylmethanol ethers, Bis(4-fluorophenyl)methanes, All stub articles, Nervous ...
September 2012). "R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant ... another dopamine re-uptake inhibitor) fail to reduce cocaine self-administration. Atypical DRIs like modafinil that bind to the ... "Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use ... Modafinil acts as an atypical, selective, and weak dopamine reuptake inhibitor and indirectly activates the release of orexin ...
"Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor". European ... It also acts as a dopamine reuptake inhibitor and has stimulant effects in mice. Amfonelic acid Fluoroquinolone JP Patent ... Dopamine reuptake inhibitors, Carboxylic acids, Nitrogen heterocycles, Oxygen heterocycles, Heterocyclic compounds with 3 rings ...
"The high-affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation, and sensitization ... In contrast to cocaine and other cocaine-like dopamine reuptake inhibitors, JHW-007 binds to the dopamine transporter (DAT) in ... JHW-007 is a cocaine analog and a high affinity atypical dopamine reuptake inhibitor that is being researched for the treatment ... Articles with short description, Short description matches Wikidata, Cocaine, Dopamine reuptake inhibitors, Stimulants). ...
"Comparative behavioral pharmacology of cocaine and the selective dopamine uptake inhibitor RTI-113 in the squirrel monkey". The ... is a stimulant drug which acts as a potent and fully selective dopamine reuptake inhibitor (DRI). It has been suggested as a ... "Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus ... Wee S, Carroll FI, Woolverton WL (February 2006). "A reduced rate of in vivo dopamine transporter binding is associated with ...
Izenwasser S, Werling LL, Cox BM (June 1990). "Comparison of the effects of cocaine and other inhibitors of dopamine uptake in ... "A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects". ... "Nicotinic acetylcholine receptor antagonistic property of the selective dopamine uptake inhibitor, GBR-12909 in rat hippocampal ... Dopamine reuptake inhibitors, Nicotinic antagonists, 1-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperazines, VMAT inhibitors). ...
"Combinations of Cocaine with Other Dopamine Uptake Inhibitors: Assessment of Additivity". Journal of Pharmacology and ... between Conformational Changes in the Dopamine Transporter and Cocaine-Like Subjective Effects of Uptake Inhibitors". Molecular ... Rothman, RB; Baumann, MH; Prisinzano, TE; Newman, AH (2008). "Dopamine transport inhibitors based on GBR12909 and benztropine ... In animal studies, certain of the local anesthetics have displayed residual dopamine reuptake inhibitor properties, although ...
... the antidepressant tianeptine is not a dopamine uptake inhibitor". Pharmacology Biochemistry and Behavior. 63 (2): 285-90. doi: ... and the drug appears to act predominantly as a dopamine reuptake inhibitor. In contrast to the case for dopamine, amineptine ... Dopamine releasing agents, Hepatotoxins, Laboratoires Servier, Norepinephrine-dopamine reuptake inhibitors, Tricyclic ... It acts as a selective and mixed dopamine reuptake inhibitor and releasing agent, and to a lesser extent as a norepinephrine ...
Izenwasser S, Werling LL, Cox BM (June 1990). "Comparison of the effects of cocaine and other inhibitors of dopamine uptake in ... Pu C, Fisher JE, Cappon GD, Vorhees CV (June 1994). "The effects of amfonelic acid, a dopamine uptake inhibitor, on ... In studies, it proved to be a potent and highly selective dopamine reuptake inhibitor (DRI) in rat brain preparations. A study ... AFA remains a widely used pharmacological tool for study of the brain's reward system, dopamine pathways, and the dopamine ...
Wong DT, Bymaster FP (September 1978). "An inhibitor of dopamine uptake, LR5182, cis-3-(3,4-dichlorophenyl)-2-n,n- ... an inhibitor of uptake into dopamine and norepinephrine neurons". Neuropharmacology. 18 (5): 497-501. doi:10.1016/0028-3908(79) ... alkane dopamine uptake inhibitors". Journal of Medicinal Chemistry. 42 (5): 882-95. doi:10.1021/jm980566m. PMID 10072685. ... LR-5182 is a stimulant drug which acts as a norepinephrine-dopamine reuptake inhibitor, structurally related to the better ...
Lane EL, Cheetham S, Jenner P (March 2005). "Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats ... It inhibits the synaptic reuptake of dopamine, serotonin and noradrenaline, making it a triple reuptake inhibitor. It was ... to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS ... Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P (January 2004). "The monoamine reuptake inhibitor BTS 74 398 fails to ...
Conventional dopamine re-uptake inhibitors (such as cocaine or methylphenidate) would otherwise ineffectively target such a ... This increases the inhibition of re-uptake at synaptic dopamine concentrations without interfering in the flow of release of ... inhibiting the re-uptake of dopamine, but does not modulate d-amphetamine-induced DA release by inhibiting that as well, like ' ... SoRI-20041 is believed to be the first example of a drug that separately modulates uptake versus release in the dopamine ...
... for dopamine releasers/substrates is entropy-driven (i.e. hydrophobic), whereas for dopamine re-uptake inhibitors it is ... "Thermodynamic analyses of the binding of substrates and uptake inhibitors on the neuronal carrier of dopamine labeled with [3H] ... and dopamine are known (serotonin-norepinephrine-dopamine releasing agents, or SNDRAs), however. Serotonin-dopamine releasing ... A closely related type of drug is a dopamine reuptake inhibitor (DRI). Various selective DRIs are known, in contrast to the ...
July 2014). "UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without ... it is one of the few selective SDRIs or serotonin-dopamine reuptake inhibitors). This change causes UWA-101 to lack ... Both are active monoamine reuptake inhibitors. Another relative is UWA-104 ("α-isopropyl-MDMA"), which is also active. MBDB ... while retaining high serotonin transporter affinity and markedly increasing affinity for the dopamine transporter (and as such ...
... the dopamine re-uptake inhibitor Both enantiomers of phenylpiracetam have been described in peer-reviewed research as dopamine ... The patent asserts discovery of phenylpiracetam's action as a dopamine reuptake inhibitor as its basis. The peculiarity of this ... Norepinephrine-dopamine reuptake inhibitors, Phenyl compounds, Racetams, Russian drugs, Russian inventions, Stimulants, World ... Their action at the noradrenaline transporter vary: the R enantiomer acts as a noradrenaline reuptake inhibitor (thus, an NDRI ...
... over norepinephrine and dopamine uptake) inhibitor of the reuptake of serotonin that was never marketed. It also has moderate ... Selective serotonin reuptake inhibitors, Tricyclic antidepressants, All stub articles, Nervous system drug stubs). ... a Selective 5-Hydroxytryptamine Reuptake Inhibitor". Drug Development Research. 29 (3): 235-248. doi:10.1002/ddr.430290311. ...
"Dopamine Uptake Inhibitors but Not Dopamine Releasers Induce Greater Increases in Motor Behavior and Extracellular Dopamine in ... Norepinephrine reuptake inhibitor (NRI) Selective norepinephrine reuptake inhibitor (sNRI) Dopamine reuptake inhibitor (DRI) ... Serotonin-dopamine reuptake inhibitor (SDRI) Norepinephrine-dopamine reuptake inhibitor (NDRI) Serotonin-norepinephrine- ... A monoamine reuptake inhibitor (MRI) is a drug that acts as a reuptake inhibitor of one or more of the three major monoamine ...
2008). "In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor". European Journal of ... A serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), is a type of ... 2. Potent dopamine and serotonin reuptake inhibitors". Journal of Medicinal Chemistry. 43 (6): 1215-1222. doi:10.1021/jm9905561 ... Chen Z, Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs. 2007 ...
... indirect effects on dopamine. The effectiveness of dopamine re-uptake inhibitors in treating the symptoms of ADHD has led to ... Both methylphenidate and amphetamines block re-uptake of dopamine and norepinephrine into the pre-synaptic neuron, acting to ... Some of these genes are: DAT1 is the dopamine transporter gene which is responsible for the active reuptake of dopamine from ... DRD4 is the dopamine D4 receptor gene and is associated with ADHD and novelty seeking behaviors. It has been proposed that ...
... a different dopamine uptake inhibitor. These inhibitory properties are responsible for the stimulatory effects of dimethocaine ... Just like cocaine, dimethocaine inhibits the uptake of dopamine in the brain by interfering with the dopamine transporters. The ... and their potency to inhibit dopamine uptake. In studies with rhesus monkeys the affinity of dimethocaine for dopamine ... by blocking dopamine transporters (DAT). The dopamine transporter controls the dynamics of the neurotransmitter dopamine. This ...
... and other inhibitors of norepinephrine uptake sites are able to inhibit the binding of 3H-NIS. When rats are ... Norepinephrine, along with dopamine and/or other serotonin reuptake inhibitors, are often prescribed in the treatment of mood ... 3H-nisoxetine (3H-NIS), on the other hand, is a potent and selective inhibitor for the uptake of norepinephrine and is now used ... It is 400-fold more potent in blocking the uptake of norepinephrine than that of dopamine. The R-isomer of nisoxetine has 20 ...
... and blocks uptake of 3H-Norepinephrine into rat heart. Tametraline is a norepinephrine-dopamine reuptake inhibitor. Indatraline ... 1R-Methylamino-4S-phenyl-tetralin is a potent inhibitor of norepinephrine uptake in rat brain synaptosomes, reverses reserpine ... Koe BK (December 1976). "Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal ... a new uptake inhibitor with selectivity for serotonin". The Journal of Pharmacology and Experimental Therapeutics. 226 (3): 686 ...
Dopamine reuptake inhibitors, Stimulants, Local anesthetics, Methyl esters, Isothiocyanates, Covalent inhibitors, All stub ... as well as irreversible blocker of dopamine uptake by DAT (the latter being unlike its C3 homologue m-Isococ). p-Isococ also ... R)-p-Isothiocyanatobenzoylecgonine methyl ester (p-ISOCOC) is a cocaine analogue and irreversible (covalent) binding inhibitor ... biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter". Journal of ...
... induced dopamine release and free radical formation in the mouse striatum J Neurochem 2002 81(5):961-972 ... on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine (ecstasy)- ... on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine (ecstasy)-induced dopamine ... on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine (ecstasy)-induced dopamine ...
Inhibitors of arachidonic acid metabolism: effects on rat striatal dopamine release and uptake.. W A Cass, G Larson, F A ... Inhibitors of arachidonic acid metabolism: effects on rat striatal dopamine release and uptake.. W A Cass, G Larson, F A ... Inhibitors of arachidonic acid metabolism: effects on rat striatal dopamine release and uptake.. W A Cass, G Larson, F A ... Inhibitors of arachidonic acid metabolism: effects on rat striatal dopamine release and uptake. ...
Dopamine Uptake Inhibitors PubMed MeSh Term *Overview. Overview. subject area of * Adenosine A(2A) Receptors in the Nucleus ... Terminal Dopamine Release Kinetics in the Accumbens Core and Shell Are Distinctly Altered after Withdrawal from Cocaine Self- ... Tropomyosin-Related Kinase B in the Mesolimbic Dopamine System: Region-Specific Effects on Cocaine Reward Journal Article ... Prior Cocaine Experience Impairs Normal Phasic Dopamine Signals of Reward Value in Accumbens Shell Journal Article ...
The idea that dopamine modulates novelty seeking is supported by evidence that novel stimuli excite dopamine neurons and ... Dopamine Plasma Membrane Transport Proteins / metabolism * Dopamine Uptake Inhibitors / pharmacology * Exploratory Behavior / ... In addition, dopamine is shown to drive exploratory behavior in novel environments. It is not clear whether dopamine promotes ... The idea that dopamine modulates novelty seeking is supported by evidence that novel stimuli excite dopamine neurons and ...
Amphetamine and dextroamphetamine, non-catechloamine sypathomimetic agents, are used in combination to treat attention-deficit hyperactivity disorder (ADHD) or narcolepsy. Adderall consists of equivalent amounts of amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate ...
Dopamine Uptake Inhibitors / administration & dosage * Drug Administration Schedule* * Drug Delivery Systems* * Forecasting ...
"Synthesis of 3-arylecgonine analogues as inhibitors of cocaine binding and dopamine uptake". Journal of Medicinal Chemistry. 33 ... Troparil is a few times more potent than cocaine as a dopamine reuptake inhibitor, but is less potent as a serotonin reuptake ... Troparil is a phenyltropane-based dopamine reuptake inhibitor (DRI) that is derived from methylecgonidine. ... dopamine uptake inhibition, and locomotor stimulant activity of 2-substituted 3 beta-phenyltropane derivatives". Journal of ...
Combinations of Cocaine with Other Dopamine Uptake Inhibitors: Assessment of Additivity. Journal of Pharmacology and ... Mazindol Analogues as Potential Inhibitors of the Cocaine Binding Site at the Dopamine Transporter. Journal of Medicinal ... 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) Analogues: A Promising Class of Monoamine Uptake Inhibitors. ... Discovery of Drugs to Treat Cocaine Dependence: Behavioral and Neurochemical Effects of Atypical Dopamine Transport Inhibitors ...
LR: 20131121; JID: 100909747; 0 (Dopamine Uptake Inhibitors); 01ZG3TPX31 (Bupropion); epublish. Place of Publication ...
... dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)- ... dopamine releasers and dopamine uptake inhibitors was the same ((+)-Amph > > pCA = MDMA > > (+)-Fen). We also confirmed that ... Lack of extracellular Ca2+ did not alter uptake mechanisms nor did it modify the carrier-dependent dopamine-induced [3H]- ... dopamine release. (+)-Amph-induced [3H]-dopamine release and pCA- and MDMA-induced [3H]-5-HT release were significantly ...
2013) Mathematical model of dopamine autoreceptors and uptake inhibitors and their influence on tonic and phasic dopamine ... The inhibitor was modeled by increasing Kapp, the apparent Michaelis-Menten constant for DAT-mediated uptake. Note that ... 2001) Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. J ... In this regime, nonspecific uptake plays a vanishing role in the model. Consequently, MAO-B inhibitors, also used in PD therapy ...
The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization C ... The Dopamine Uptake Inhibitor 3a-[bis(40-fluorophenyl)metoxy]-tropane Reduces Cocaine-Induced Early-Gene Expression, Locomotor ... The novel dopamine inhibitor uptake 3 -[(bis-4´-fluorophenyl)methoxy]-tropane (AHN-1055) prevents cocaine-induced place ... A Dopamine Transport Inhibitor with Markedly Low Abuse Liability Suppresses Cocaine Self-Administration in the Rat A. Ferragud ...
Dopamine agonists can take the form of re-uptake inhibitors, others fit the dopamine receptors. Some operate by both mechanisms ...
Amphetamine and the dopamine uptake inhibitor GBR-12909 increased ambulation in SHRs and WKY to a similar extent. Central ...
... a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Retrieved from https://www.ncbi.nlm.nih. ... The extra dopamine provides a cognitive boost, helping you think better and get more stuff done [11, 12]. ... Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther. 2009 ... This is thought to be due to the fact that Modafinil increases levels of both histamine and dopamine in the brain, which helps ...
Stimulants are Dopamine re-uptake inhibitors. Kids with ADHD have lower than normal levels of dopamine in their brain. The re ... uptake inhibitors work by interrupting the normal flow of dopamine in the neuronal synapse. Normally, unused dopamine flows ... The inhibitors block the pathway back to the pre-synapse and trap the dopamine in the neuronal cleft. The Child now has ... Selective Serotonin Re-uptake Inhibitors (SSRIs) work basically the same way.. Clinical Depression and Schizophrenia are ...
... and it acts as a competitive inhibitor of the transporter reducing uptake of dopamine. Amphetamine enters the cell mainly ... Amphetamine is also substrate for vesicular monoamine transporter 2 (VMAT2) preventing the uptake of dopamine into storage ... It also enhances dopamine synthesis and according to recent studies amphetamine augments exocytotic dopamine release. Drug ... Two food additives were dual inhibitors. IC50 values were determined in dose-response studies for the potential inhibitors. The ...
The design and synthesis of novel derivatives of the dopamine uptake inhibitors GBR 12909 and GBR 12935. High-affinity ... High affinity inhibitors of the dopamine transporter (DAT): novel biotinylated ligands for conjugation to quantum dots. ID ... Serotonin uptake is largely mediated by platelets versus lymphocytes in peripheral blood cells. BS Beikmann, ID Tomlinson, SJ ... Inhibitors of the serotonin transporter protein (SERT): the design and synthesis of biotinylated derivatives of 3-(1, 2, 3, 6- ...
... has been found to act as a potent neurocompetitive dopamine inhibitor of dopamine uptake by nerve endings when exposed in vitro ... There is now some evidence that a reduced dopamine turnover may lead to childhood hyperactivity.121 Similar findings have been ... Lafferman JA and Silbergeld EK: Erythro-sin B inhibits dopamine transport in rat caudate synaptosomes. Science, 205: 410-412, ... Snyder SH: Putative neurotransmitters in the brain: selective neuronal uptake, subcellular localization, and interactions with ...
nicotine is a dopamine re-uptake inhibitor….. ….which means that only people with low dopamine levels would. get any effect… ... people whos system didnt create enough dopamine, are susceptible to addiction, for chemical ingesting would release dopamine ... Changes in dopamine availability? - okay, maybe. But the main problem is that we dont want to say that opiate addiction is a ... And sex and love ride on dopamine waves that recede to backwaters when the love object isnt around. So biological changes are ...
N2 - Objective: Solriamfetol (formerly JZP-110), a dopamine/norepinephrine reuptake inhibitor, is approved in the US to improve ... AB - Objective: Solriamfetol (formerly JZP-110), a dopamine/norepinephrine reuptake inhibitor, is approved in the US to improve ... Objective: Solriamfetol (formerly JZP-110), a dopamine/norepinephrine reuptake inhibitor, is approved in the US to improve ... abstract = "Objective: Solriamfetol (formerly JZP-110), a dopamine/norepinephrine reuptake inhibitor, is approved in the US to ...
Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine. In addition, Bupropion does not ... Monoamine oxidase inhibitors. Monoamine oxidase inhibitors. Mechanism of action. MAOIs act by inhibiting the activity of ... Is Lexapro an MAO inhibitor?. Lexapro is not considered a monoamine oxidase inhibitor (MAOI). MAOIs work by slowing down the ... Is Prozac a MAO inhibitor?. Prozac is the brand name of the drug fluoxetine, a selective serotonin reuptake inhibitor (SSRI). ...
Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine and does not inhibit monoamine ... 7.6 MAO Inhibitors. Bupropion inhibits the reuptake of dopamine and norepinephrine. Concomitant use of MAOIs and bupropion is ... 7.6 MAO Inhibitors 7.7 Drug-Laboratory Test Interactions 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 ... Inhibitors of CYP2B6 Ticlopidine and Clopidogrel: In a study in healthy male volunteers, clopidogrel 75 mg once daily or ...
... dopamine uptake inhibitors, serotonin, tryptamine, muscimol, melatonin, or dopamine itself produced release. The cells capable ... There was a dose- and calcium-dependent release of dopamine from turtle retinas incubated in $\sp3$H-dopamine after perfusion ... of the release of dopamine were identified using both uptake autoradiography and immunocytochemical localization with dopamine ... This indicated that dopamine release was tonically inhibited by GABA. Other putative retinal transmitters were examined. ...
Dopamine Uptake Inhibitors * Extinction, Psychological * Intracellular Signaling Peptides And Proteins * Male * Naphthyridines ...
I can hold my own with any psychiatrist because I know and understand terms like selective serotonin re-uptake inhibitor, ... titration, GABA, dopamine agonist, and efficacy. However, these terms mean absolutely nothing to the average person, who must ...
... a selective dopamine and norepinephrine reuptake inhibitor. Baladi, M. G., Forster, M. J., Gatch, M. B., Mailman, R. B., Hyman ... Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Gatch, M. B., Taylor, C. M., Flores, E., Selvig, M. ...
SSRIs inhibit central nervous system (CNS) neuronal uptake of serotonin (5HT). They may also have a weak effect on ... selectively inhibits presynaptic serotonin reuptake with minimal or no effect on the reuptake of norepinephrine or dopamine. ... Selective Serotonin Reuptake Inhibitors. Class Summary. SSRIs are first-line agents for managing anxiety, depression, avoidance ...

No FAQ available that match "dopamine uptake inhibitors"